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ABSTRACT 
 Metastatic dissemination of ovarian tumors involves the invasion of multi-
cellular tumor cell clusters into the mesothelial cell lining of organs in the 
peritoneal cavity. We developed an in vitro assay that models this initial step of 
ovarian cancer metastasis to investigate the mechanisms of invasion. Pre-
clustered ovarian cancer multicellular spheroids are incubated with GFP-
expressing mesothelial monolayers and the extent of mesothelial invasion is 
monitored by time-lapse video microscopy.   
 Time-lapse microscopy revealed that ovarian cancer spheroids intercalate 
into mesothelial monolayers, protrude under the mesothelial cells, trigger 
mesothelial cell matrix adhesion disassembly, and ultimately, mesothelial cell 
migration away from the intercalating spheroid. Mechanistic studies 
demonstrated that actomyosin-generated contractile force exerted by the ovarian 
cancer spheroid, via !5"1 integrin, myosin II, and Talin I, on the fibronectin 
matrix surrounding the mesothelial cells is required for clearance of the 
mesothelial monolayer.  
  To more comprehensively investigate the mechanisms regulating 
mesothelial clearance, we examined the clearance ability of a large panel of 
established ovarian cancer cell lines. Approximately two-thirds of the cells lines 
produced spheroids that were clearance-competent, while one-third of the cell 
! "#!
lines produced spheroids that were clearance-incompetent. Microarray analysis 
revealed that genes in an Epithelial to Mesenchymal (EMT) core signature were 
enriched in clearance-competent cell lines, while epithelial genes were enriched 
in clearance-incompetent cell lines. The importance of this signature was 
supported experimentally; over-expression or knockdown of EMT-inducing 
transcription factors promoted or attenuated clearance, respectively. The role of 
EMT in mesothelial clearance was further supported in a more clinically relevant 
panel of primary cell samples; clearance-competent primary cell spheroids were 
enriched for the mesenchymal marker, vimentin, while clearance-incompetent 
primary cell spheroid were enriched for the epithelial marker, E-cadherin.   
The studies in this dissertation revealed that cellular components 
implicated in the regulation of cell adhesion and migration -- namely integrin 
matrix receptor complexes and actomyosin contractility -- drive mesothelial 
clearance by ovarian cancer spheroids. In addition, our data strongly suggest 
that tumor cells that display a mesenchymal phenotype play a more significant 
role in mesothelial clearance. These findings provide a framework for future 
studies on the mechanisms of clearance by ovarian cancer spheroids.  
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Chapter 1 
Introduction 
 Ovarian cancer is the fifth leading cause of cancer mortality among 
women in the United States with over 22,000 new cases diagnosed each year (1, 
2). Typically, ovarian cancer remains undetected until patients present with late 
stage metastatic disease (stage III/IV) (3), resulting in the highest death-to-
incidence ratio of any cancer (1). Screening methods, including blood tests and 
ultrasounds, are ineffective, as they are unable to detect small tumor masses and 
often produce false positives (4, 5). The current treatment options for ovarian 
cancer involve cytoreductive surgery followed by platinum/taxane-based 
chemotherapy. Patients often respond well to these first-line treatments (6-8), 
however relapse is common. The mortality of ovarian cancer is a consequence of 
the excessive tumor bulk that results from peritoneal metastases. In fact, the 
volume of tumor bulk correlates with poor overall survival in ovarian cancer 
patients (9, 10). It is therefore, very important to understand the mechanisms by 
which ovarian cancer cells seed peritoneal metastases, in order to determine 
how seeding can be prevented, and develop treatments that target the cells are 
not effectively eradicated by current treatments.  
 
Ovarian Cancer Subtypes: 
 Ovarian Cancer is classified into four major subtypes: Serous, 
Endometrioid, Clear Cell and Mucinous. Serous carcinomas are the most 
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common, accounting for 60-80% of all cases. Endometrioid carcinomas are the 
second most common accounting for 8-19%, while mucinous carcinomas 
account for 3-11% and clear cell carcinomas account for less that 5% of all 
ovarian carcinomas(11-13). While it was previously thought that all ovarian 
cancers developed in the tissues of the ovary, it is now becoming apparent that 
most ovarian cancers are derived from non-ovarian tissue and more closely 
resemble the mullerian-derived tissue of the reproductive tract (6, 14). 
Endometrioid and clear cell tumors resemble the endometrial lining of the uterus 
and are believed to develop when retrograde menstrual flow carries endometrial 
tissue from the uterus to the peritoneal cavity, causing endometriosis. This 
mislocalized endometrial tissue forms tumors in the ovary (14, 15). Tubal ligation 
has been shown to protect against endometrioid and clear cell ovarian cancer, 
presumably because retrograde endometrial flow is inhibited (16). Mucinous 
ovarian cancer, unlike the other three subtypes of ovarian cancer, does not 
resemble mullerian-derived tissues. Instead, mucinous cancers resemble the 
tissue of the gastrointestinal mucosa (14, 17).   
 High Grade Serious ovarian cancer is the most aggressive of all the 
ovarian cancer subtypes. While serous ovarian carcinomas were originally 
thought to be derived from the ovarian surface epithelium, there is increasing 
evidence that the fallopian tube fimbria is the site of origin of serous ovarian 
carcinoma (18-21). Serous ovarian carcinomas express PAX8, a mullerian 
marker, and their genetic profiles share more similarity with fallopian tube 
epithelial cells than ovarian surface epithelial cells (22-24). p53 mutations are 
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found in 96% of all high grade ovarian serous carcinomas (2, 25-27) and identical 
p53 mutations are often found in both serous tubal intraperitoneal carcinomas 
(STICS) [lesions in the fallopian tube that are though to be early occurrences of 
the disease] and concomitant high grade serous carcinomas (18, 19, 28, 29), 
further suggesting that the fallopian tube is the site of origin of serous ovarian 
cancer.     
 The different subtypes of ovarian cancer display varying degrees of 
metastatic aggressiveness. Clear cell, mucinous, low-grade endometrioid and 
low-grade serous carcinomas are generally confined to the ovary when they 
present, whereas high-grade serous and high-grade endometrioid carcinomas 
are highly metastatic. Therefore, the subtype of ovarian cancer should be taken 
into account when studying the mechanisms of ovarian cancer metastasis.      
 
Ovarian Cancer Metastasis:  
 Typically, metastatic events occur when tumor cells separate from a 
primary tumor that is embedded deep within a tissue and migrate through 
collagen I rich connective tissue to blood or lymph vessels.  Once in contact with 
a vessel, the cells intravasate and travel to new sites where they attach to the 
endothelium, extravasate, and invade surrounding tissues (30). Ovarian cancer 
metastasis proceeds differently, however. There is no anatomical barrier to 
peritoneal metastasis so intravasation and extravasation are not required for 
spread of the ovarian tumors. Rather, malignant cells are shed from the primary 
tumor and collect in the peritoneal cavity, where they are disseminated by the 
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physiological movement of the peritoneal fluid (3, 6). Malignant cells can be 
found as both single cells and cell aggregates (spheroids) within the peritoneal 
cavity and single cells can aggregate within the peritoneal cavity to form clusters 
(31-33). The aggregates then settle on the surface of peritoneal cavity organs 
where they attach and disaggregate (31, 34). 
 All of the surfaces within the peritoneal cavity, including the bowel serosa, 
omentum, diaphragm, and peritoneum, are lined with a single layer of 
mesothelial cells (3, 35). The mesothelial monolayer acts as a low friction surface 
that regulates the transport of fluid and solutes between the peritoneal cavity, 
interstitial space and circulation. Directly beneath the mesothelial layer is a 
basement membrane composed of collagen types I and IV, laminin and 
fibronectin; fibroblasts and macrophages are found dispersed within these 
extracellular matrix (ECM) molecules (36). Ultrastructural analyses of ovarian 
cancer nodules attached to peritoneal cavity organs using electron microscopy 
revealed that mesothelial cells are absent from underneath the attached tumor 
mass (37), suggesting that ovarian cancer cell aggregates invade into the 
mesothelial lining of the peritoneal cavity, displace the mesothelial cells and 
attach to the underlying basement membrane. The nodules rarely invade deeper 
into the basement membrane, however, or metastasize further via the 
vasculature (3, 32, 38). It is, therefore, very important to understand the 
mechanisms of ovarian cancer invasion through and displacement of the 
mesothelial monolayer (a process we refer to as “mesothelial clearance”) so that 
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better treatment options, which take these mechanisms into account, can be 
developed. 
 
Mechanisms Governing Ovarian Cancer Spheroid Invasion into 
Mesothelial Monolayers:  
Current Studies of Ovarian Cancer Cell Attachment and Spreading:  
The goal of my dissertation research was to further understand the 
mechanisms that regulate mesothelial clearance by ovarian cancer spheroids. 
Previously published mechanistic studies focused predominantly on the cell 
adhesion molecules that mediate ovarian cancer spheroid attachment to 
mesothelial monolayers and ovarian cancer spheroid spreading on ECM-coated 
glass. Ovarian cancer cells from established cell lines and from the ascites fluid 
of ovarian cancer patients are able to attach to and spread on ECM components 
including, collagen I, collagen IV, laminin and fibronectin, as well as on cultured 
mesothelial cell monolayers (34, 39-42). Integrins are the major ECM receptors 
that mediate attachment to the ECM. Ovarian cancer cell adhesion and 
spreading on both ECM components and mesothelial monolayers has been 
shown to be inhibited by incubating the ovarian cancer cells with !1-integrin 
neutralizing antibodies (40, 43-45). " integrins, including "5, "6 and "V, have 
also been implicated in the adhesion of ovarian cancer cells to ECM and 
mesothelial monolayers, but the extent of the effects depend on the ovarian 
cancer cell line and ECM component studied (40, 41, 43, 46-49). In addition to 
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integrins, the cell adhesion molecule CD44 can promote ovarian cancer cell 
binding to mesothelial cell monolayers (45, 50, 51).  
While ovarian cancer cell adhesion has been well studied, there has been 
much less focus on the mechanisms required for the ovarian cancer cells to 
invade into mesothelial monolayers or collagen rich basement membranes. 
Ahmed and colleagues found that !3, !6, and "1-integrin neutralizing antibodies 
significantly decreases the ability of HEY ovarian cancer cells to invade through 
Boyden chambers coated with Matrigel (43) and several groups have shown that 
inhibiting VCAM, a4-integrin, "1-integrin, MMP-2, or MMP-9 reduces the 
migration of single ovarian cancer cells through a mesothelial monolayer (46, 52, 
53). Together, these studies suggest that cell adhesion molecules play a role in 
ovarian cancer cell adhesion and invasion, but they do not address the role of 
integrins in mesothelial clearance by ovarian cancer multicellular spheroids.   
To characterize mesothelial invasion, Burleson and colleagues incubated 
OVCA5 ovarian cancer spheroids on a mesothelial monolayer and found that the 
spheroids adhered and disaggregated on top of the monolayer (34, 42). While 
the authors concluded that the spheroids had invaded into the mesothelial 
monolayer, neither the ovarian cancer cells nor the mesothelial cells were 
labeled in any way that would allow the two populations to be distinguished, so 
the extent of invasion and displacement of the mesothelial monolayer could not 
be measured with this model system.  We have developed an in vitro model 
system that uses fluorescently-labeled mesothelial cells to distinguish the ovarian 
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cancer cells from the mesothelial monolayers, allowing for the measurement of 
mesothelial clearance (Chapter 2).  
   
Cell Migration Machinery:  
Cell migration plays an important role in many physiological processes: e.g. 
during development, large groups of cells migrate collectively to form the three 
germ layers of the embryo (54); during immune surveillance, leukocytes migrate 
from the circulation to surrounding tissues (55); and during renewal of the skin 
and intestinal tissue, new epithelial cells migrate up from the basal layer and 
crypts, respectively (56). It is likely that ovarian cancer cells use mechanisms 
involved in these normal migratory processes to invade into mesothelial 
monolayers.  
Using confocal microscopy, we observed that ovarian cancer spheroids 
invade into the mesothelial monolayer by protruding between the mesothelial 
cells, adhere to the underlying surface, and translocating beneath the monolayer 
cells. These actions promote the mesothelial displacement as the spheroid 
continues to spread. Protrusion, adhesion and translocation are all steps of the 
cell migration cycle, so we initially chose to focus on the components of the cell 
migration machinery during our investigation of the mechanisms regulating 
mesothelial clearance. Furthermore, the increased migratory and invasive ability 
of cancer cells has been linked to increased contractile force produced by the 
cancer cell (57). We therefore, sought to determine if molecules involved in 
contractile force generation during migration could also regulate mesothelial 
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clearance.    
Four components of the cell migration machinery that are important for 
force generation are actin, myosin, integrins, and talin (58, 59). Actin is one of the 
components of the cytoskeleton that is responsible for maintaining cell shape and 
remodeling of the actin cytoskeleton regulates migration and invasion (60). It is 
present in the cell in two forms, a monomeric G-actin and a filamentous F-actin. 
Actin filaments are polarized; the positive (barbed) end has a much higher 
monomer on-rate than off-rate, while the negative (pointed) end has a higher 
monomer off-rate than on-rate, which promotes growth of the actin filament from 
the positive end only (61). The actin cytoskeleton produces forces on the 
extracellular environment in two ways: through protrusions created when actin 
polymerizes against the cell membrane and through contractions produced with 
the help of the motor protein myosin (59, 62, 63). 
Myosin is a plus end motor protein that contains a head, neck and tail 
domain. The head domain binds to actin, while the tail domain binds the tail 
domains of other myosin molecules, therefore, myosin strengthens the actin 
network by cross-linking actin fibers. When the heads of opposing myosin 
molecules retract, they pull actin filaments in opposite directions, causing the 
actin network to contract (64).   
Integrins are transmembrane proteins that connect the cytoskeleton to the 
extracellular matrix (65, 66). The extracellular domain of an integrin binds with 
specificity to ECM molecules (67, 68), while the intracellular domain attaches to 
actin polymers via adaptor proteins, such as talin (69). Integrins are 
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heterodimeric proteins that contain non-covalently bound alpha and beta 
subunits; the combination of different alpha and beta subunits determines the 
ECM molecules that the integrin can bind to (70, 71). Integrins can exist in either 
an active-state, where they are unfolded and bound to ECM molecules, or in an 
inactive-state, where they are folded and not bound to ECM molecules; integrins 
can rapidly switch between these states to attach and detach from the ECM 
during processes such as cell migration (59, 72-74). 
Talin acts as a bridge that links integrins to the actin cytoskeleton by either 
binding directly to the beta subunit of integrins and actin filaments or binding to 
these molecules indirectly via vinculin and !-actinin (75, 76). Together, the 
actomyosin network, talin and integrins work together to aid in cell migration. 
While there are several other molecules that mediate force transduction during 
cell migration, we will not discuss them here because they were not the focus of 
our studies.  
 
Cell Migration Cycle:  
The cell migration cycle begins when the cells sends out actin-rich cell 
membrane protrusions (58, 59, 61). Next, integrins in the protrusions are 
activated and the extracellular subunits bind to ECM while cytoplasmic tail binds 
to the actin cytoskeleton via adaptor proteins including Talin (76, 77). Contraction 
of the actomyosin network exerts force on the talin and integrin containing 
adhesions, which in turn exerts force on the ECM attached to the integrins. This 
force promotes the recruitment of additional integrins and signaling molecules to 
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the growing adhesion, promoting adhesion maturation (69). Finally, actomyosin 
contractility causes retraction of the cell rear and promotes focal adhesion 
disassembly in the back of the cell and protein recycling to the leading edge (78-
81). When this process repeats in a polarized fashion, the cell is able to migrate 
in a specific direction.   
The ability of a cell to polarize and migrate directionally is regulated by 
various signaling molecules, including the Rho family of GTPases (82). The Rho 
GTPases, RAC, RHOA and CDC42, are small G proteins that bind guanosine 
triphosphate (GTP) molecules. Guanine nucleotide exchange factors (GEFs) 
activate Rho GTPases by swapping GDP molecules that are bound by the 
GTPases with GTP molecules. GTPase activating proteins (GAPs) deactivate 
Rho GTPases, by promoting the hydrolysis of bound GTP to GDP(83, 84). Rho 
GTPases regulate many of the components of cell migration machinery and the 
spatial regulation of active Rho GTPases promote directional cell migration (85). 
For example, RAC and CDC42 stimulate Arp2/3, a protein complex that 
facilitates actin filament nucleation and branching, which produces lamellipodial 
protrusions (83, 86). RHOA induces actomyosin contractility, which is responsible 
for focal adhesion maturation and turnover in the cell rear. RHOA and RAC are 
mutually antagonistic (87). RAC is more active at the leading edge of a migrating 
cell due to the RAC GEFs that are activated by PI3 kinases at the leading edge, 
while RHOA is more active at the sides and rear(58). RHOA inhibits RAC at the 
sides and rear of the cell, preventing protrusions from occurring in locations other 
than the leading edge (88, 89).  This spatial regulation restricting protrusions to 
10
the front of the cell and retractions to the back of the cell promotes directional cell 
migration.   
 
Force Transmission from the Cell to the Extracellular Matrix:  
Not only do focal adhesions mediate the attachment of a cell to its 
extracellular environment to promote cell migration, they are also sites of force 
transmission where the contractile force produced by the actomyosin network is 
transmitted to the ECM via actin and talin (62). Cells are able to sense the 
stiffness of the ECM and remodel the cytoskeleton accordingly; less stiff 
substrates resist less tension and as a result the focal adhesions are unable to 
mature as they would on stiffer substrates (90, 91). Furthermore, as force is 
exerted on the ECM via focal adhesions, the ECM is remodeled. ECM 
remodeling has been shown to play a role in the collective migration of tumor 
cells. During collective migration of squamous cell carcinoma, fibroblasts migrate 
and remodel the ECM so that they align in the direction of the cell movement, 
and this remodeling is force dependent. The squamous cell carcinoma cells then 
follow the tracks of remodeled ECM to metastasize to new sites (92, 93). It is 
likely that, during mesothelial clearance by ovarian spheroids, the force exerted 
by the spreading ovarian cancer cells on the ECM surrounding the monolayer 
cells plays a role in regulating ovarian cancer spheroid invasion into the 
monolayer.   
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The Epithelial to Mesenchymal Transition and Cancer 
Metastasis: 
 The Epithelial to Mesenchymal Transition (EMT) is a transcriptional 
program that imparts increased migratory and invasive ability on cells. EMT is 
believed to occur during cancer progression, to convert immotile primary tumors 
cells to motile cells that can travel to secondary sites. Expression of EMT-
inducing transcription factors SNAI1, ZEB1 and TWIST1 have been associated 
with tumor recurrence, metastasis and poor prognosis in many cancer, including 
breast, colon, squamous cell, colorectal, uterine, and prostate, and hepatocellular 
carcinomas (94-107). Furthermore, there is evidence linking transcription factors 
that regulate EMT with ovarian cancer invasion and progression. The expression 
of SNAIL, TWIST and ZEB1 is associated with metastasis and poor overall and 
progression-free survival in ovarian cancer (108-114). This raises the question of 
whether the EMT program may regulate mesothelial clearance during ovarian 
cancer metastasis. 
  
What is EMT?  
EMT is a process whereby apicobasal-polarized, immotile epithelial cells 
that are linked by cell-cell adhesions are converted to planar-polarized, migratory 
mesenchymal-like cells that display tractable cell-cell adhesions, increased 
invasiveness, resistance to apoptosis, and increased production of ECM 
components (115, 116).  The epithelial and mesenchymal cell states can be 
thought of as two extremes on a continuum, as cells with varying degrees of 
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epithelial and mesenchymal characteristics have been observed. The reverse 
process, a Mesenchymal to Epithelial Transition (MET), can also occur (115, 
117).  
EMT occurs in several biological contexts: during embryo implantation, 
trophectoderm cells in the blastocyst undergo EMT to invade into the 
endometrium and anchor the placenta; during gastrulation, cells in a single germ 
layer migrate to produce three germ layers; during vertebrate nervous system 
development, epithelial cells located near the dorsal midline of the neural tube 
are converted to mesenchymal cells that migrate to distinct regions within the 
embryo (118-120); during wound healing, tissue regeneration and organ fibrosis, 
EMT converts epithelial cells to fibroblasts that reconstruct tissue after trauma or 
injury due to inflammation (121-123); and during neoplastic transformation, non-
migratory epithelial carcinoma cells convert to migratory cells that physically 
detach from a primary tumor and metastasize to distant sites. Cells with the 
hallmarks of EMT transformation have been observed at the invasive front of 
primary tumors (124-127).   
 During development, EMT is induced by receptor tyrosine kinases that are 
activated by signaling molecules such as fibroblast growth factor (FGF), platelet 
derived growth factor (PDGF), epidermal growth factor (EGF), transforming 
growth factor-! (TGF!), and vascular endothelial growth factor (VEGF) (125, 
128, 129). These growth factors induce multiple transcription factors that have 
been shown to regulate programs associated with EMT, including SNAIL, SLUG, 
TWIST1, TWIST2, ZEB1, ZEB2, Goosecoid and FOXC2 (130). All of these 
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transcription factors regulate the expression of target genes that ultimately 
control the EMT phenotype (131). 
SNAIL and SLUG, members of the snail family of transcription factors, are 
zinc finger transcriptional repressors (132). Each protein contains a highly 
conserved C-terminal region with four zinc fingers that act as sequence specific 
DNA binding domains that recognize consensus E2-box DNA binding elements. 
The N-terminal domain of the proteins contains a nuclear export sequence and a 
destruction box that regulate the proteins localization and function when subject 
to phosphorylation and other post-translational modifications (133-136). 
TWIST1 and TWIST2 protein are class II bHLH proteins that each contain 
two parallel amphipatic ! helices that are joined by a loop region. They bind to 
target DNA sequences as heterodimers with class I bHLH proteins. The proteins 
can act as transcriptional activators or repressors by recruiting molecules, such 
as histone acetyltransferases or deacetylases, that regulate transcription via 
post-translational DNA modifications (137, 138). 
Members of the ZEB family (including ZEB1 and ZEB2) are E-box DNA 
binding proteins that contain two zinc finger clusters on either end of a 
homeodomain. The two zinc finger domains bind with high affinity to the E-box 
DNA sequences to induce or repress transcription (139-142).  
In addition to transcription factors, microRNAs act downstream of growth 
factors to regulate EMT. miR10b, miR21, miR373 and miR520c positively 
regulate EMT, migration and invasion, while miR126, miR206, miR335 and 
miR200 suppress EMT (143, 144). For example, members of the miR200 family 
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of microRNAs can prevent EMT by blocking ZEB1 function (145). 
 During EMT, the transcription factors and microRNAs above repress the 
expression of epithelial genes, including E-cadherin, claudins, cytokeratins, 
mucins, plakophilin, occludin, syndecan, and ZO proteins, and enhance the 
expression of mesenchymal genes, including N-cadherin, vimentin, !-SMA, 
fibronectin and !5"1 integrin (115, 146). Transcriptional regulation of these 
genes can be direct or indirect (130, 131). Taube and coworkers identified a core 
signature of EMT gene that are consistently up-regulated or down-regulated in 
response to several conditions of EMT induction (146) -- Goosecoid, SNAIL or 
TWIST1 overexpression, TGF" treatment, or E-cadherin knockdown -- in human 
mammary epithelial cells (HMEC). An overlapping set of 159 genes were down-
regulated and 87 genes were up-regulated at least 2-fold as a result of each of 
those perturbations. Genes that were down-regulated included the epithelial 
genes E-cadherin, Keratin-18 and Rab25 while genes that were up-regulated 
included the mesenchymal genes N-cadherin, vimentin and ZEB1. This set of 
genes, therefore, represented a minimal set of genes that are associated with 
EMT in HMECs (146).   
 
EMT in Cancer:  
 As stated previously, the expression of EMT-associated transcription 
factors is associated with ovarian cancer progression and metastasis (94-107). In 
addition, the expression of mesenchymal markers, including vimentin, !-SMA 
and laminin 5, or the repression of the epithelial marker E-cadherin, are 
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associated with invasiveness and metastasis in several types of cancer(127, 
147-150). Furthermore, inducing EMT in cells promotes invasiveness. For 
example, over-expression of ZEB1 in epithelial cells results in a loss of E-
cadherin expression and induction of invasion (149) and overexpression of 
FOXC2 or Goosecoid in weakly metastatic human carcinoma cells increases 
their ability to disseminate (151, 152). This suggests that EMT plays an important 
role in cancer progression, but how is EMT induced within the tumor 
microenvironment?   
 The induction of EMT has been studied extensively in breast cancer cells. 
Weinberg and colleagues have shown that components of the tumor stroma are 
able to induce EMT in epithelial carcinoma cells. They showed that breast cancer 
cells recruit mesenchymal stem cells to the breast-cancer associated stroma 
(153). IL-1 secreted by the breast cancer cells induces the mesenchymal stem 
cells to produce PGE2, IL-6, IL-8, and GRO-!. All of these cytokines secreted by 
the mesenchymal stem cells then induce EMT in the breast cancer cells(154).  
 Once outside of the EMT promoting microenvironment, cancer cells can 
maintain the mesenchymal-like state in a paracrine fashion if EMT inducing 
cytokines are in the new environment or in an autocrine fashion if the cancer 
cells produce their own cytokines. If these signaling loops are inhibited, the 
mesenchymal-like cancer cells convert back to an epithelial state (155).  
 The fact that mesenchymal-like cells lose their mesenchymal features and 
revert back to epithelial-like cells when they are removed from an environment 
with EMT-inducing cytokines suggests that carcinoma cells do not constitutively 
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express the properties that allow them to invade and metastasize, but rather only 
transiently become invasive in response to the microenvironment to which the 
cell is exposed (153). The reversion of mesenchymal-like carcinoma cells to an 
epithelial-like state may facilitate proliferate at the distant metastatic site (125, 
156). This transient nature of EMT has made it difficult to observe EMT in vivo, 
which is why the existence of EMT during cancer metastasis is still under debate.  
 
EMT in Ovarian Cancer:  
 The microenvironment and mode of metastasis of ovarian cancer is very 
different compared to that of breast cancer, however, so it is unclear if EMT plays 
a role in ovarian cancer metastasis, or how or when EMT would be induced in 
ovarian cancer cells. Several studies have attempted to address the role of EMT 
in ovarian cancer. Increased SNAI1 expression is associated with the degree of 
malignancy and overall survival in ovarian cancer. Specifically, increased SNAI1 
expression in metastases is correlated with poor overall survival (108). Higher 
SNAI1 expression is observed in late stage ovarian cancer patients compared to 
early stage patients and SNAI1 protein expression is significantly lower in ovarian 
cancer effusions compared to primary and solid metastases (109, 110). TWIST1 
is associated with shorter overall and progression free survival in ovarian cancer 
(108, 111, 112) and high levels of ZEB1 mRNA are observed in high-grade 
serous ovarian carcinomas (113). Furthermore, the expression levels of TWIST1, 
ZEB1 and vimentin are higher in metastases compared to primary tumors and 
effusions (114). The majority of studies on the role of E-cadherin in ovarian 
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cancer suggest a prognostic role in the disease. Loss of overall E-cadherin 
expression is associated with poor survival and low E-cadherin mRNA 
expression in carcinoma effusions is correlated with poor survival, as well (113). 
In high-grade serous ovarian carcinoma, high expression of E-cadherin and low 
expression of N- and P-cadherin are associated with better survival (157). These 
observations suggest that EMT plays a role in ovarian cancer progression. 
Experimental data showed that EMT-inducing transcription factors could 
regulate the attachment of ovarian cancer cells to ECM and mesothelial 
monolayers and invasion through Matrigel. Down-regulation of SNAI1 or TWIST1 
expression in ES2 or HEY ovarian cancer cells, respectively, suppressed 
invasion through Matrigel (114, 158). Furthermore, knockdown of PAK1, a known 
regulator of SNAI1, reduced ES2 cell attachment to ECM and mesothelial cell 
monolayers (114). TWIST1 overexpression in OVCA433 and OVCA432 ovarian 
cancer cells increased adhesion to ECM and mesothelial cell monolayers as well 
(112, 158). These studies did not, however, address the role of EMT-inducing 
transcription factors in mesothelial clearance by ovarian cancer cells.   
 
Characterization of Mesothelial Clearance: 
 We first sought to describe the process of mesothelial clearance by 
ovarian cancer spheroids. Time-lapse, confocal microscopy revealed that ovarian 
cancer spheroids intercalate into mesothelial monolayers, protrude under the 
mesothelial cells, trigger mesothelial cell matrix adhesion disassembly, and 
ultimately, mesothelial cell migration away from the intercalating spheroid. 
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We showed that inhibiting !5"1 integrin, myosin II or Talin I function, in a 
clearance-competent cell line, inhibits mesothelial clearance. Furthermore, over-
expression of !5 integrin in a clearance-incompetent cell line promotes 
mesothelial clearance. We show that !5"1 integrin reorganizes the fibronectin 
matrix surrounding the mesothelial cells and blocking !5"1 integrin function 
inhibits fibronectin remodeling.  Furthermore, we show that over-expressing !5 
integrin in ovarian cancer cells increases the amount of traction force exerted by 
the cell, while inhibiting myosin II or talin I function in the !5 integrin over-
expressing cells blocks the increase in traction force cause by !5 integrin. Taken 
together, these experiments suggest that ovarian cancer spheroids use 
actomyosin generated traction force, via talin and !5"1 integrin, to drive 
mesothelial clearance (Chapter 3).     
 
Transcriptional Regulation of Mesothelial Clearance: 
 To comprehensively and systematically investigate the mechanisms 
regulating mesothelial clearance, we measured clearance ability in large panels 
of both established ovarian cancer cell lines and primary ovarian cancer cells 
isolated from the ascites of ovarian cancer patients. Comparison of the clearance 
ability of 20 established ovarian cancer cell lines revealed that genes in an EMT 
core signature were enriched in clearance-competent compared to clearance-
incompetent cell lines. Overexpression of EMT transcription factors in clearance-
incompetent ovarian cancer spheroids promoted mesothelial clearance, while 
inhibition of EMT transcription factors in clearance-competent cell lines 
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attenuated mesothelial clearance. The correlation of EMT with mesothelial 
clearance was also found in a more clinically relevant large panel of primary 
ovarian tumor cell samples; clearance-competent primary cell spheroids were 
enriched for the mesenchymal marker, vimentin, while clearance-incompetent 
primary cell spheroids were enriched for the epithelial marker, E-cadherin. This 
heterogeneity was also observed in different subpopulations of tumor cells from 
the same primary patient sample. Taken together, these data suggest that a 
mesenchymal phenotype promotes mesothelial clearance ability by ovarian 
cancer spheroids (Chapter 4).  
The findings in this dissertation provide important new insights into the 
mechanisms associated with metastatic progression of ovarian cancer and 
provide a framework for future studies on the mechanisms of clearance by 
ovarian cancer spheroids. 
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Chapter 2 
In vitro Mesothelial Clearance Assay that Models 
the Early Steps of Ovarian Cancer Metastasis 
 
Statement of Contribution:  
This chapter embodies a manuscript published in the Journal of Visualized Experiments 
by R.A. Davidowitz, M.P. Iwanicki and J.S. Brugge*. I wrote the manuscript and 
performed the mesothelial clearance assay in the video. MPI developed the assay. MPI 
and JSB participated in the writing of the manuscript.    
 
*Corresponding authors 
 
Journal of Visualized Experiments Video: 
See Supplementary Movie 2.1 or  
www.jove.com/video/3888/in-vitro-mesothelial-clearance-assay-that-
models-early-steps-ovarian 
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Short Abstract:  
The mesothelial clearance assay described here takes advantage of 
fluorescently labeled cells and time-lapse video microscopy to visualize and 
quantitatively measure the interactions of ovarian cancer multicellular spheroids and 
mesothelial cell monolayers. This assay models the early steps of ovarian cancer 
metastasis.  
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Long Abstract:  
Ovarian cancer is the fifth leading cause of cancer related deaths in the United 
States(1). Despite a positive initial response to therapies, 70 to 90 percent of women 
with ovarian cancer develop new metastases, and the recurrence is often fatal(2). It is, 
therefore, necessary to understand how secondary metastases arise in order to develop 
better treatments for intermediate and late stage ovarian cancer. Ovarian cancer 
metastasis occurs when malignant cells detach from the primary tumor site and 
disseminate throughout the peritoneal cavity. The disseminated cells can form 
multicellular clusters, or spheroids, that will either remain unattached, or implant onto 
organs within the peritoneal cavity(3) (Figure 2.1).  
 All of the organs within the peritoneal cavity are lined with a single, continuous, 
layer of mesothelial cells(4-6) (Figure 2.2). However, mesothelial cells are absent from 
underneath peritoneal tumor masses, as revealed by electron micrograph studies of 
excised human tumor tissue sections(3, 5-7) (Figure 2.2). This suggests that 
mesothelial cells are excluded from underneath the tumor mass by an unknown 
process.  
    Previous in vitro experiments demonstrated that primary ovarian cancer cells 
attach more efficiently to extracellular matrix than to mesothelial cells(8), and more 
recent studies showed that primary peritoneal mesothelial cells actually provide a 
barrier to ovarian cancer cell adhesion and invasion (as compared to adhesion and 
invasion on substrates that were not covered with mesothelial cells)(9, 10). This would 
suggest that mesothelial cells act as a barrier against ovarian cancer metastasis. The 
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cellular and molecular mechanisms by which ovarian cancer cells breach this barrier, 
and exclude the mesothelium have, until recently, remained unknown.  
 Here we describe the methodology for an in vitro assay that models the 
interaction between ovarian cancer cell spheroids and mesothelial cells in vivo (Figure 
2.3). Our protocol was adapted from previously described methods for analyzing 
ovarian tumor cell interactions with mesothelial monolayers(8-16), and was first 
described in a report showing that ovarian tumor cells utilize an integrin –dependent 
activation of myosin and traction force to promote the exclusion of the mesothelial cells 
from under a tumor spheroid(17).  This model takes advantage of time-lapse 
fluorescence microscopy to monitor the two cell populations in real time, providing 
spatial and temporal information on the interaction. The ovarian cancer cells express 
red fluorescent protein (RFP) while the mesothelial cells express green fluorescent 
protein (GFP). RFP-expressing ovarian cancer cell spheroids attach to the GFP-
expressing mesothelial monolayer. The spheroids spread, invade, and force the 
mesothelial cells aside creating a hole in the monolayer. This hole is visualized as the 
negative space (black) in the GFP image. The area of the hole can then be measured to 
quantitatively analyze differences in clearance activity between control and 
experimental populations of ovarian cancer and/ or mesothelial cells. This assay 
requires only a small number of ovarian cancer cells (100 cells per spheroid X 20-30 
spheroids per condition), so it is feasible to perform this assay using precious primary 
tumor cell samples. Furthermore, this assay can be easily adapted for high throughput 
screening.      
 
39
40
Protocol Text: 
1. Ovarian Cancer Cell Spheroid Formation 
1.1 RFP-expressing ovarian cancer cells are cultured in 10% Base Medium (a custom 
cell culture medium containing a 50:50 mixture of 199 and MCDB105, 10% inactivated 
fetal bovine serum and 1% pen-strep). To express RFP in unlabeled ovarian cancer 
cells, transfect the cells with a plasmid containing RFP and select for cells expressing 
RFP. Alternatively, viral vectors can be used to transiently express fluorescent proteins, 
or cells can be pre-incubate with a red fluorescent cell tracker dye (Invitrogen).  
1.2 Prior to forming of ovarian cancer spheroids, it is necessary to prepare low-adhesion 
96 well round bottom culture dishes. To produce the low-adhesion culture plates, 30ul 
poly-HEMA (6mg polyhydroxyethylmethacrylate in 95% EtOH) solution is added to each 
well of a 96 well Corning cell culture dish. The 96 well plates are incubated in a 37°C 
non-humidified incubator to evaporate the ethanol, leaving a film of poly-HEMA on each 
well. This poly-HEMA film prevents cells from attaching to the bottom of the well, forcing 
the cells to grow in suspension(18). [Alternatively, Ultra-Low Attachment culture plates 
(Corning) can be used instead of poly-HEMA coated dishes.] 
1.3 After the low-adhesion culture plates are prepared, trypsinize a plate of ovarian 
cancer cells, pellet the cells in a tabletop centrifuge (Heraeus) at 900 RCF for 3 
minutes, aspirate the supernatant and re-suspend in 10% Base Medium.  
1.4 Count the cells using a hemocytometer. 
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1.5 Adjust the concentration of cells such that there are 100 cells per 50ul of 10% Base 
Medium. 
1.6 Add 50ul of the uniformly suspended diluted cell suspension to each well of the 96 
well poly-HEMA coated culture dish. 
1.7 Incubate the 96 well plate in a 37°C cell culture incubator for 16 hours (this amount 
of time should be increased or decreased depending on the amount of time it takes for a 
particular cell line to form multicellular spheroids or desired experimental conditions) to 
allow the ovarian cancer cells to cluster together, forming a single multicellular spheroid 
in each well. Some tumor cells can undergo apoptosis during this period, so it is 
important to choose a time prior to induction of apoptosis.  
2. Mesothelial Cell Monolayer Formation  
2.1 In a cell culture hood, pre-coat the wells of a 6 well glass-bottom MatTek dish with 
fibronectin by adding 2mL of a 5ug fibronectin/ mL PBS solution to each well of the dish 
and incubating at room temperature for 30 minutes. The optical quality of the glass-
bottoms in MatTek dishes allow for high-resolution microscopic imaging.   
2.2 GFP-expressing mesothelial cells are cultured in 10% Base Medium. Trypsinize a 
plate of mesothelial cells, spin down in a tabletop centrifuge (Heraeus) at 900RPM for 3 
minutes, aspirate the supernatant, and re-suspend in 10% Base Medium. The 
mesothelial cells used here were already expressing GFP when they were obtained, but 
unlabeled mesothelial cells can be produced by transfecting with a plasmid containing 
GFP cDNA, or preincubating the cells in a green fluorescent cell tracker dye 
(Invitrogen).  
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2.3 After the 30-minute fibronectin incubation (in step 2.1), wash the wells of the MatTek 
dish with 2mL PBS.  
2.4 Aspirate the PBS and plate 3x105 mesothelial cell per well in each well of the 6 well 
MatTek dish. Incubate the MatTek dish in a 37°C cell culture incubator overnight to 
allow the mesothelial cells to attach to the dish and form a monolayer. 
3. Mesothelial Cell Clearance Assay 
3.1 Use a pipet to collect the ovarian cancer spheroids from the 96 well poly-HEMA 
coated plate.  
3.2 Aspirate the medium from one well of the 6 well MatTek dish containing a 
mesothelial cell monolayer. Wash once with 2mL PBS. Add all of the spheroids from the 
96 well plate to one well of the MatTek dish (~3x the number of spheroids that are going 
to be imaged to account for spheroids landing on the part of the dish that cannot be 
imaged).  
3.3 Place the MatTek dish on the stage of an inverted widefield fluorescence 
microscope capable of performing time-lapse imaging for the duration of at least 8 
hours. Use a motorized stage to image multiple positions in the dish, with multiple 
spheroid intercalation events, in a single experiment. We use a Nikon Ti-E Inverted 
Motorized Widefield Fluorescence time-lapse microscope with integrated Perfect Focus 
System and low [20!-0.75 numerical aperture (NA)] magnification/NA differential 
interference contrast (DIC) optics, a Nikon halogen transilluminator with 0.52 NA long 
working distance (LWD) condenser, Nikon fast (<100-millisecond switching time) 
excitation and emission filters (GFP Ex 480/40, Em 525/50, RFP-mCherry Ex 575/50 
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Em 640/50), Sutter fast transmitted and epifluorescence light path Smart Shutters, a 
Nikon linear-encoded motorized stage, a Hamamatsu ORCA-AG cooled charge-coupled 
device (CCD) camera, a custom-built microscope incubation chamber with temperature 
and CO2 control, Nikon NIS-Elements AR software version 3, and a TMC vibration 
isolation table. 
3.4 The ovarian cancer cell spheroids will settle to the bottom of dish and attach to the 
mesothelial cell monolayer. Collect GFP, RFP and phase images of 20+ 
spheroid/monolayer interactions, every 10 minutes, for 8 hours.   
3.5 The RFP-expressing ovarian cancer cell spheroids will invade into the GFP-
expressing mesothelial cell monolayer creating a hole in the monolayer. After 8 hours, 
measure the sizes of the holes by tracing the black holes in the GFP images using 
Elements software (or another suitable software such as image J) . Normalize the hole 
size to the initial spheroid size by dividing the hole size at 8 hours by the size of the 
spheroid in the corresponding RFP image at time zero. In this example, the hole size 
was only measured once, but it can be measured multiple times throughout the eight 
hour experiment to better understand the dynamics of intercalation. 
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Representative Results:  
In this example, we compared the mesothelial clearance ability of OVCA433 
ovarian cancer cell spheroids that have attenuated expression of talin-1 and -2 to 
control OVCA433 spheroids. OVCA433 spheroids from each group were added to a 
MatTek dish containing ZT mesothelial cell monolayers. Six spheroids from each group 
were imaged every 10 minutes for eight hours (Figure 2.4). The holes produced in the 
monolayer by the spreading spheroids were measured and six positions from each 
group were averaged. Figure 2.4 shows that the average clearance area created by 
talin 1 and 2 knockdown spheroids was significantly smaller than the average area 
created by control spheroids, suggesting that talin is required for mesothelial clearance 
by OVCA433 ovarian cancer spheroids.   
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Discussion: 
 The “Mesothelial Clearance Assay” presented here uses time-lapse microscopy 
to monitor the interactions of ovarian cancer multicellular spheroids and mesothelial cell 
monolayers, in great spatial and temporal detail. Previously, several groups(8-14) had 
used endpoint assays to show that ovarian cancer cells attach to and invade into 
mesothelial cell monolayers. This assay is unique in that it uses fluorescently labeled 
cells to distinguish tumor cells from mesothelial cells, so that the dynamics of these two 
cell populations can be monitored throughout the assay. The process of intercalation 
can be visualized in real time and the rate of mesothelial clearance can be quantitatively 
measured over time. The use of timelapse microscopy allows one to closely monitor the 
dynamics of the interaction between the two cell populations under different 
experimental conditions. Additionally, a small percentage of either the mesothelial cells 
or the ovarian cancer cells can be labeled with a third fluorescent marker to monitor the 
dynamics of individual cells within the population. By tracking individual cells over time, 
the directionality and rate of migration can be calculated. To perform higher resolution 
analyses of mesothelial clearance, total internal reflection fluorescence (TIRF) 
microscopy can be used. If focal adhesions are labeled in the mesothelial cells, the 
dissociation of mesothelial adhesions by protrusive extensions of the tumor cells can be 
monitored, as described in our previous publication(17).  
This assay can be used to compare the invasion ability of ovarian cancer cell 
spheroids that have been genetically or pharmacologically modified to elucidate the 
molecular mechanisms by which ovarian cancer cell spheroids clear the mesothelial 
monolayer or to identify small molecule inhibitors of the process. Furthermore, the 
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assay requires a very small number of ovarian cancer cells, so primary tumor cells from 
fluid exudates can be used (see limitations below) if labeled by preincubating the cells 
with cytotracker dyes (Invitrogen). The assay is also amenable to high throughput 
analysis. To perform high throughput genetic or pharmacological studies, the ovarian 
cancer cells can be transfected with different siRNA vectors or treated with different 
pharmacological inhibitors in each well of the 96-well plate. Mesothelial cell monolayers 
can be plated in 96 well glass-bottom culture dishes, and the spheroids can be 
transferred 1:1 from the poly-HEMA coated plates to the monolayer-containing plates. 
All of these steps can be optimized for use with screening robots so that hundreds of 
siRNAs or inhibitors can screened at one time.   
One of the strengths of this assay is to be able to model the force-dependent 
intercalation of ovarian cancer cells into the mesothelial monolayer. Our lab used 
traction force microscopy (TFM) to determine whether mechanical force regulates 
mesothelial clearance(17). We found that overexpression of !5 integrin increased the 
contractility of cells plated on a fibronectin-coated substrate, while RNAi-mediated 
knockdown of talin, or myosin II decreased cell contractility(17). Since downregulation of 
!5 integrin, talin, or myosin II in the ovarian cancer cell spheroids also decreased 
mesothelial clearance, our TFM measurements support the idea that mesothelial 
clearance in an event dependent on cellular contractile forces, in which cells with higher 
contractile forces caused greater mesothelial clearance. Therefore, the mesothelial 
clearance assay can be used to further understand intercalation events, associated with 
ovarian spheroid metastasis, that are dependent on mechanical forces.       
48
 This assay has a few limitations to consider. First, in order to form the 
multicellular spheroids, the cells must be cultured in suspension for at least 6 hours. If 
the cells are unable to survive without matrix contact their clearance ability will be 
compromised. Second, it is advantageous to use ovarian cancer cells that form uniform, 
compact multicellular spheroids. If the ovarian cancer cells only form loose clusters, 
they may break apart in the transfer from the polyHEMA-coated plate to the dish 
containing the mesothelial monolayer, creating spheroids of different shapes and sizes 
that will add variability to the data. Third, if the cells used are heterogeneous, this will 
add additional variability to the sizes of holes created in the monolayer. It is important to 
use multiple replicate wells (10-20/sample) due to the variability in extent of intercalation 
after eight hours. In the assays described here, well-established ovarian cancer 
(OVCA433) and mesothelial (ZT) cell lines were used. To make this assay more 
clinically relevant, primary ovarian cancer cells, from the ascites fluid of patients, can be 
used. It would be interesting to determine if in vitro mesothelial cell clearance ability 
correlates with clinical outcome. The limitations above are particularly important to 
consider when using primary samples, as the number of primary cells available is a 
limiting factor. Additionally, it is important to check the integrity of the mesothelial 
monolayer before performing this assay. The mesothelial monolayer can be fixed and 
stained for cell-cell junction proteins to ensure that mesothelial cell junctions are intact. 
 Finally, the mesothelial clearance assay can be easily modified to answer 
specific experimental questions. Here, we used fibronectin as the ECM component that 
allows the ovarian and mesothelial cells to adhere to the glass-bottom culture dishes, 
however, other ECM components can be used including collagen and laminin. 
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Furthermore, other cell types that are found under the basement membrane, including 
fibroblasts, can be added to this experimental system, to assess the role of these cell 
types in mesothelial clearance(9, 19, 20). Lastly, interactions of other types of tumor 
cells (e.g. pancreatic, breast, etc) with mesothelial cells can also be modeled using this 
assay.  And it is feasible to study interactions between cancer cells and an endothelial 
monolayer, using this assay, to mimic intravasation or extravasation (Similar assays 
have been described in: (15, 16, 21-27)) 
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Table 2.1: Specific Reagents and Equipment 
Reagent Company Catalog 
Number 
Comments 
OVCA433 Ovarian Cancer 
Cells 
  Gift from Dr. Dennis 
Slamon 
ZT Mesothelial Cells   Gift from Dr. Tan 
Ince 
Medium 199 Gibco 19950  
MCDB105 Cell Applications 
Inc. 
117-500  
FBS-heat inactivated Gibco 10082  
Pen-Strep Gibco 15070  
96 well plates Corning Costar 3799  
Polyhydroxyethylmethacryl
ate (poly-HEMA) 
Sigma Aldrich 192066-25G For poly-HEMA 
solution dissolve 6mg 
poly-HEMA powder 
in 1ml of 95% EtOH 
EtOH Pharmco-aaper 111ACS200 Dilute to 95% in 
dH20 
Cell culture hood Nuaire NU-425-300  
Tissue culture incubator Thermo Scientific 3110  
incubator for poly-HEMA 
plates 
Labline Instruments Imperial III 
305 
 
Tabletop centrifuge Heraeus 75003429/01  
6 well glass-bottom dish MatTek corp. P06G-1.5-
20-F 
 
Fibronectin Sigma F1141-1MG  
PBS Cellgro 21-040-CV  
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Table 2.1, cont’d. 
Timelapse Microscope:    
Microscope Nikon  Ti-E Inverted 
Motorized 
Fluorescence time-
lapse microscope 
with integrated 
Perfect Focus 
System 
Lens Nikon  20X-0.75 numerical 
apeture 
Halogen transilluminator Nikon  0.52 NA long working 
distance condenser 
Excitation and emission 
filters 
Chroma single pass 
filters in Nikon 
housing 
 GFP Ex 480/40, Em 
525/50  
RFP-mCherry Ex 
575/50 Em 640/50 
Transmitted and 
Epifluoresce light path  
Sutter  Smart Shutters 
Linear-encoded motorized 
stage 
Nikon   
Cooled charged-coupled 
device camera 
Hamamatsu ORCA-AG  
Microscope incubation 
chamber with temperature 
and CO2 control 
custom-built   
Vibration isolation table TMC   
NIS-Elements software Nikon  Version 3 
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!Chapter 3 
Ovarian Cancer Spheroids Use Myosin-
generated Force to Clear the Mesothelium 
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!Abstract: 
Dissemination of ovarian tumors involves the implantation of cancer spheroids 
into the mesothelial monolayer on the walls of peritoneal and pleural cavity organs. 
Biopsies of tumors attached to peritoneal organs show that mesothelial cells are not 
present under tumor masses. We have developed a live, image-based in vitro model in 
which interactions between tumor spheroids and mesothelial cells can be monitored in 
real time to provide spatial and temporal understanding of mesothelial clearance. Here 
we provide evidence that ovarian cancer spheroids utilize integrin – and talin - 
dependent activation of myosin and traction force to promote mesothelial cells 
displacement from underneath a tumor cell spheroid. These results suggest that ovarian 
tumor cell clusters gain access to the sub-mesothelial environment by exerting force on 
the mesothelial cells lining target organs, driving migration and clearance of the 
mesothelial cells.  
 
Significance: 
This study employs state of the art microscopy to reveal that ovarian cancer cell 
clusters physically displace mesothelial cells and gain access to the sub-mesothelial 
environment. Blockade of force- conducting molecules including !5 integrin, talin I and 
non-muscle myosin II in cancer cells abrogated mesothelial displacement from 
underneath attached cancer spheroids. 
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!Introduction: 
During the progression of ovarian cancer, tumor cells detach from the primary 
tumor site and form cell clusters, or spheroids, that can either remain unattached in the 
peritoneal cavity or implant onto peritoneal organs (1). Formation of implants depends 
on the ability of tumor cells to invade into the mesothelial layer that covers peritoneal 
and pleural organs (2). Electron micrographs of mesothelial tissue sections with and 
without peritoneal metastases (3, 4) revealed that normal peritoneal mesothelial cells 
are flat and cover the entire surface of the peritoneum, such that cell-cell boundaries are 
difficult to discern, whereas, the mesothelial cells with peritoneal metastases are more 
rounded and separated from each other, revealing the sub-mesothelial surface. These 
studies suggested that mesothelial cells retracted in the presence of the tumor. 
Furthermore, the cancer cells did not adhere to the mesothelial cells, but rather to 
connective tissue under the mesothelial cells. In addition, electron micrographs of 
excised human peritoneum-associated tumors revealed that mesothelial cells are not 
present directly under the tumor mass, suggesting mesothelial clearance from the area 
beneath the tumor mass (4). Early, in vitro, experiments also provided evidence that 
mesothelial cells retract after coming in contact with tumor cells (5, 6). In these studies 
ovarian cancer cell clusters disrupted mesothelial cell-cell junctions and penetrated 
matrix under mesothelial cells, suggesting that the integrity of the mesothelial cell 
monolayer is altered by the attached tumor cells that bind with high affinity to sub-
mesothelial matrix,(6, 7). The cellular and molecular mechanisms of mesothelial 
clearance, however, are unknown. 
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!We have used a live, image-based in vitro model in which interactions between 
tumor spheroids and mesothelial cells can be monitored in real time to provide spatial 
and temporal understanding of the process of mesothelial clearance. Using this model, 
we demonstrate that tumor spheroid attachment and spreading on a mesothelial 
monolayer promotes clearance of the mesothelial cells from the area underneath the 
spheroid. We provide evidence that force generation on the mesothelial cell-associated 
extra-cellular matrix provokes mesothelial cells to migrate and clear from underneath 
the tumor spheroid. This mechanism might be relevant to processes involved in 
implantation of ovarian tumor aggregates into the sub-mesothelial environment of the 
organs of the peritoneal and pleural cavities. 
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!Results: 
Interaction of ovarian cancer spheroids with mesothelial monolayers promotes 
mesothelial cell clearance. 
To investigate the interaction between ovarian cancer spheroids (OVCA433 
ovarian cancer cell line) and GFP-expressing mesothelial cells (normal immortalized 
lung mesothelium), we used time-lapse microscopy to follow the dynamics of a 
mesothelial monolayer after cancer spheroid attachment, in real time. As the spheroid 
spread on the mesothelial monolayer, mesothelial cells were displaced from the area 
directly underneath the spreading spheroid. This phenomenon will be referred to as 
mesothelial clearance. (Figure 3.1A and Supplementary Movie 3.1). The clearance area 
increased with time as the spheroid became more incorporated into the mesothelial 
monolayer (Figure 3.1B). We also observed that primary tumor clusters isolated from 
the peritoneal fluid of ovarian cancer patients are able to attach to and clear the 
mesothelium (Figure 3.1C and Supplementary Movie 3.2). Overall, these data indicate 
that, following attachment to a mesothelial monolayer, clusters of ovarian cancer cells 
are able to induce clearance of the mesothelial cells directly underneath the tumor 
spheroid.  
In vivo, mesothelial cells are separated from the underlying soft connective tissue by a 
layer of matrix (8). To examine whether mesothelial clearance can occur on more 
physiologically relevant substrates (of similar stiffness to connective tissue), mesothelial 
monolayers were plated on fibronectin-coated polyacrylamide gels with elastic moduli of 
0.3 kPa or 10kPa. OVCA433 tumor spheroids were able to induce mesothelial 
clearance on both substrates (Supplementary Figure 3.1A), indicating that mesothelial 
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!clearance can indeed occur on softer, more physiologically relevant substrates, and that 
the mesothelial clearance observed is not an artifact of cells grown on stiff glass 
surfaces. 
To study the spheroid-mesothelial interaction more closely, we imaged a 
spheroid during the process of intercalation into a mesothelial monolayer in multiple 
focal planes and reconstructed the x-z planes to observe ovarian-mesothelial cell 
interactions at the ventral and dorsal cell surfaces. In the early stages of clearance (as 
shown in Figure 3.1D and Supplementary Movie 3.3), cancer cells spread on top of the 
monolayer (as indicated by the arrows) and then penetrated under the mesothelium (as 
indicated by *). From these observations, we hypothesized that cancer spheroids 
adhere to the mesothelial monolayer and induce localized de-adhesion of the 
mesothelial cells to ultimately prompt movement of the mesothelial cells away from the 
spheroid.  
To examine whether localized de-adhesion of mesothelial cell matrix adhesions 
indeed occurs upon contact with a tumor spheroid, we used Total Internal Reflection 
Fluorescent Microscopy (TIRFM) to monitor mesothelial cell adhesions labeled with 
paxillin-GFP (this protein localizes to integrin-matrix engagement sites in multiple cell 
types). TIRFM allows for the visualization of florescent molecules present within 100nm 
above the surface of the cover slip, thereby minimizing background intensity from 
cytoplasm. We observed that cancer spheroids (labeled with RFP-actin) approached the 
mesothelial cell’s adhesions (GFP) and promoted matrix adhesion disassembly (Figure 
3.2A and Supplementary Movie 3.4). Furthermore, there was little adhesion assembly 
within the area of contact. In contrast, mesothelial cell matrix adhesions that were not in 
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!contact with a tumor spheroid displayed spontaneous adhesion assembly and 
disassembly events (Figure 3.2B and Supplementary Movie 3.5). In a separate 
experiment, we labeled approximately one in 500 mesothelial cells with GFP to track the 
movement of individual mesothelial cells and observed that mesothelial cells that 
contacted a cancer spheroid migrated significantly longer distances than the mesothelial 
cells that did not contact a cancer spheroid (Figure 3.2C,D and Supplementary Movie 
3.6). Overall, our results are consistent with the hypothesis that ovarian cancer 
spheroids can attach to a mesothelial monolayer, intercalate into the monolayer, and 
trigger mesothelial cell matrix adhesion disassembly and migration, ultimately leading to 
mesothelial clearance. 
 
Coupling of myosin contractility to integrins in cancer spheroids is required for 
mesothelial clearance.  
Ovarian cancer cell adhesion to a mesothelial monolayer has been shown to 
involve integrins (9). Cells exert force on the extracellular matrix by coupling myosin 
contractility to integrins (10) (11). Therefore, we examined whether tumor spheroid 
expression of myosin II is required to promote mesothelial clearance. OVCA433 cancer 
spheroids express non-muscle myosin isoforms IIA and IIB (Figure 3.3A). Both myosin 
II isoforms were downregulated in OVCA433 cells using small hairpin RNA (shRNA) 
and small interfering RNA (siRNA) targeting myosin IIA and II B heavy chain 
respectively (Figure 3.3A). Myosin heavy chain IIA and IIB attenuation did not prevent 
the ovarian cancer cells from spreading on surfaces coated with fibronectin and 
collagen I, indicating that myosin IIA and IIB are not required for spheroid attachment 
64
65
!and spreading on fibronectin and collagen coated glass surfaces (Supplementary Figure 
3.1B). However, OVCA433 spheroids with reduced levels of myosin IIA/IIB initiated but 
were unable to sustain mesothelial clearance (Figure 3.3B,C and Supplementary Movie 
3.7). Attenuation of myosin II in OVCA433 cells by shRNA/siRNA did not prevent 
adhesion of spheroids to the mesothelial monolayer (Supplementary Figure 3.1C left 
panel) or induce apoptosis (Supplementary Figure 3.1C right panel), suggesting that 
myosin II expression in these cells is dispensable for spheroid attachment. We validated 
these results with two additional independent shRNA sequences targeting myosin IIA 
combined with the same siRNA pool for myosin IIB molecules (Supplementary Figure 
3.1D). Taken together, these results suggest that OVCA433 cancer spheroids require 
myosin to induce mesothelial clearance.  
The ability of cells to exert force on the outside environment depends on linkage 
of the actin and myosin network to integrins through recruitment of talin I to adhesion 
sites (10). We used small hairpin RNA (shRNA) to attenuate the expression of talin I in 
the spheroids (Figure 3.3D). Attenuation of talin I expression in OVCA433 spheroids did 
not induce apoptosis (Supplementary Figure 3.1C right panel) and had no effect on 
spreading on glass surfaces coated with fibronectin and collagen I (Supplementary 
Figure 3.2A). However, decreased expression of talin I but not talin II significantly 
reduced mesothelial clearance, even though spheroid adherence to the monolayer was 
unaffected (Figure 3.3C,Supplementary Movie 3.8 and Supplementary Figure 3.2B,C). 
We validated these results with two additional independent shRNA sequences targeting 
talin I molecule in OVCA433, DOV13 and SKOV3 ovarian cancer cell lines 
(Supplementary Figure 3.2D). These data indicate that talin I is required for tumor cell 
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!interaction and suggest that the linkage of integrins to the actomyosin network in 
ovarian spheroids contributes to mesothelial clearance.  
 
!5"1 integrin is required for spheroid – induced mesothelial clearance and 
contributes to the activation of myosin in cancer cells  
Because expression of the !5 integrin fibronectin receptor has been shown to 
correlate with the development of myosin-driven contractility(12) and increased invasion 
of ovarian cancer cells (13, 14), we addressed whether !5"1 integrin-mediated 
activation of contractility contributes to ovarian spheroid–induced mesothelial clearance. 
First, we blocked the function of !5 integrin in cells that express high levels of !5 
integrin (OVCA433 ovarian cancer cells) (Figure 3.4 A). Treatment of OVCA433 cell 
spheroids, which express high levels of !5 integrin, with !5 integrin blocking antibody 
significantly decreased spheroid-induced mesothelial clearance (Figure 3.4B, 3.4C, 
Supplementary Movie 3.9). Blocking !5 integrin on DOV13 and SKOV3 spheroids also 
significantly decreased mesothelial clearance (Supplementary Figure 3.3A). !5 blocking 
antibodies did not, however, prevent the OVCA433 spheroids from adhering to the 
mesothelial monolayer (Supplementary Movie 3.8, and Supplementary Figure 3.3B). 
Blocking other adhesion receptors expressed by OVCA433 spheroid (data not shown), 
including CD44 and integrins !2 and !v, did not have any significant effect on spheroid-
induced mesothelial clearance (Supplementary Figure 3.3C).  
In parallel experiments, we over-expressed !5 integrin in ovarian cancer cells 
that have a low level of !5 integrin expression (OVCAR5) and are unable to clear a 
mesothelial monolayer (Supplementary Figure 3.3D). Ectopic expression of !5 integrin 
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!in OVCAR5 cells increased activation of myosin, promoted cell spreading and an 
increase in stress fibers and other cortical actin contractile structures and increased 
mesothelial clearance (Figure 3.4D,E,F and Supplementary Movie 3.10). These results 
support the hypothesis that !5"1–dependent activation of myosin in ovarian cancer 
spheroids is required for spheroid-mediated mesothelial clearance. 
 
Cancer spheroids expressing functional !5"1 integrin detach fibronectin fibrils 
from the surface of the mesothelium.  
Our data suggests that engagement of the fibronectin receptor !5"1 integrin is 
an important step in spheroid-induced mesothelial clearance. Fibronectin has been 
found to be present on the surface of murine mesothelial cells (15). Thus, we addressed 
whether ovarian cancer spheroids re-organize the fibronectin matrix presented on 
dorsal surface of the mesothelial monolayer. To determine if fibronectin is organized on 
the dorsal surface of the mesothelial monolayer, the monolayer was immunostained 
with an antibody that recognized human fibronectin. We observed that fibronectin fibrils 
were present on top of the mesothelial monolayer (Figure 3.5A and Supplementary 
Movie 3.11). We also detected organized collagen fibers on top of the mesothelium 
(data not shown); however, blocking the !2"1 integrin collagen receptor did not affect 
mesothelial clearance (Supplementary Figure 3.3C). Because fibronectin fibrils 
contacting the periphery of an intercalated spheroid appeared to be preferentially 
associated with the spheroid, but not the mesothelial cells (Supplementary Movie 3.11), 
we investigated whether cancer spheroids detach fibronectin from the mesothelial 
monolayer. We followed the dynamics of rhodamine-labeled fibronectin organized on 
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!top of the mesothelial monolayer in the presence of OVCA433 cancer spheroids. As 
shown in Figure 3.5B and Supplementary Movie 3.12, cancer spheroids induced 
detachment of fibronectin fibrils from the mesothelial cells. As time progressed, some of 
the fibronectin fibrils organized around the spheroid. In addition, when !5"1 integrin 
was inhibited by an !5 function blocking antibody, fibronectin did not dissociate from the 
mesothelial cells, suggesting that dissociation of fibronectin from the top of the 
mesothelial monolayer was dependent on functional !5"1 integrin expressed by the 
cancer spheroids (Figure 3.5C,D). These data suggest that ovarian cancer spheroids 
utilize !5"1 integrin to dissociate fibronectin from the mesothelial monolayer during 
clearance. 
 
Cancer cells exert force on a fibronectin-coated substrate in an !5"1 integrin-, 
talin 1- and myosin-dependent manner.  
The data presented above show that !5"1 integrin, myosin, and talin are all 
required in ovarian cancer cells for mesothelial clearance and that !5"1 integrin- 
dependent binding of the ovarian cancer spheroids to fibronectin organized by the 
mesothelium is important for the clearance processes. This would suggest that the 
traction force exerted on the substratum by the spreading spheroids contributes to 
mesothelial clearance. To determine if modulation of !5, talin I, or myosin affects force 
generation in the ovarian cancer cells, we used traction force microcopy (16, 17). This 
microscopy technique involves tracking fluorescent beads embedded in the substrate 
on which cell spread / migrate. Displacement of these beads is used to measure traction 
force exerted by cells on substrate during spreading/migration. Control OVCAR5 cells, 
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!OVCAR5 cells over-expressing !5 integrin, and !5 over-expressing cells treated with 
either talin I siRNA or blebbistatin were allowed to spread on fibronectin–coated 
polyacrylamide substrates embedded with fluorescently labeled beads. Spreading 
caused deformation of the substrate, as indicated by the movement of the embedded 
beads. Tracking the bead displacement and reconstructing the cellular traction stresses 
allowed us to measure the strain energy invested by the cells to deform the elastic 
substrate (16). The strain energy can be used as a measure for the contractile strength 
of cells. As shown in Figure 3.6A, increased expression of !5 integrin in cancer cells 
correlated with an increase in cellular contractility, as measured by strain energy 
exerted by the cells. !5 integrin-induced force generation was dependent on myosin 
activation because treatment of OVCAR5 cells overexpressing !5 integrin with 
blebbistatin significantly decreased elastic energy exerted on the matrix (Figure 3.5A). 
We also observed that downregulation of talin I, but not talin II, in OVCAR5 cells 
overexpressing !5 integrin decreased force generation on fibronectin substrates (Figure 
3.6B). These results are consistent with a model in which talin I and myosin act 
downstream of !5 integrin to generate force as ovarian cancer cells interact with 
fibronectin matrix.  
 
 
 
 
 
 
72
73
!Discussion: 
In summary, these studies provide new insights into the mechanism whereby 
ovarian tumor spheroids induce mesothelial cell clearance. Clearance-competent tumor 
spheroids were found to adhere to the dorsal surface of the mesothelial cells and initiate 
spreading. Protrusions from the spreading cells penetrated underneath the mesothelial 
cells causing localized breakdown of the mesothelial cell matrix adhesions, and 
provoked migration of the mesothelial cells. In tumor spheroids, !5"1 integrin, talin I 
and myosin II were found to be required for spheroid –induced mesothelial clearance. 
These experiments suggest that ovarian cancer spheroids use actomyosin contractility 
to exert force via matrix adhesion to the fibronectin organized on the mesothelial 
monolayer, ultimately leading to mesothelial clearance (see model, Figure 3.7). The 
mesothelial clearance we observe in vitro may be relevant in human tumors since it has 
been shown that mesothelial cells are not present under ovarian tumor masses found 
attached to the peritoneal tissues. 
In contrast to other epithelial tumors that employ hematogenous or 
lymphatogenous routes to metastasize, ovarian cancer cells predominantly move within 
the ascites fluid to metastasize to new sites within the peritoneal cavity(8). The 
mesothelial monolayer surface provides a variety of ligands to support the attachment of 
ovarian cancer cells (1). These ligands include hyaluronic acid, mesothelin and 
extracellular matrix molecules that are able to engage integrins (18-20). Both CD44 and 
"1-containing integrin dimers have been implicated as receptors that can mediate 
ovarian cancer cells adherence to the mesothelium. However, function-blocking 
antibodies directed against "1 integrin or CD44 only partially block ovarian cancer cells 
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!adherence to the mesothelial monolayer in short term, in vitro adhesion assays(9),(18, 
21) . This suggests that multiple ligands and receptors can support ovarian tumor cell 
adhesion to the mesothelial monolayer and targeting a single molecule will not abrogate 
cancer cell interaction with mesothelial cells. Consistent with this, we found that 
blocking CD44 or selected !1 integrin containing integrin heterodimers expressed by 
OVCA433 spheroids ("2!1, "v!3, "5!1) did not significantly block OVCA433 spheroid 
attachment to the mesothelium after 10 hours of co-culture. Interestingly, however, our 
data indicated that interfering with the function of "5!1 integrin alone can significantly 
decrease OVCA433, DOV13 and SKOV3 spheroid-induced mesothelial clearance over 
a period of 10 hours (Supplementary Figure 3.3A,C). As "5!1 integrin is a fibronectin 
receptor, these results suggest that cancer spheroids can utilize "5!1 to bind to the 
fibronectin surrounding the mesothelial cells to mediate mesothelial clearance. 
Supporting this, we found that as a spheroid clears a space in a mesothelial monolayer, 
the fibronectin fibrils organized on the top of the mesothelial cells are redistributed away 
from the mesothelial cells and under the spheroid. This process was dependent on 
functional "5!1 integrin expressed by the cancer spheroids. In addition, we also 
observed that the expression level of "5!1 integrin in various ovarian cancer cell lines 
correlated with the ability of these cells to clear the mesothelium (data not shown). 
However, it is likely that other, "5!1 integrin-independent mechanisms can mediate 
clearance as well.  
Integrins are the major molecules that can transmit traction forces to the outside 
environment (22). While "2 integrin binding to collagen I can induce fibril reorganization 
and transmit traction forces to the ECM in certain contexts (23), OVCAR5 ovarian tumor 
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!spheroids that express high levels of !2, but not !5 integrin, were unable to clear the 
mesothelium in our experiments (Supplementary Figure 3.3C). In addition, blocking !2 
integrin in OVCA433 cells that express both !2 and !5 integrin did not prevent 
mesothelial clearance (Supplementary Figure 3.3C). It is possible that !2 integrin does 
not transmit sufficient traction force under conditions of adherence to mesothelial cells 
to induce clearance of the mesothelial cells. The generation of traction force on 
fibronectin has been shown to involve two steps: First, clustering of !5"1 integrins 
promotes strong adhesiveness to matrix and second, recruitment of talin I stabilizes and 
reinforces formed !5"1 adhesions (24) promoting the exertion of traction force on the 
matrix force. Our study indicated that the interaction between fibronectin receptor !5"1 
integrin expressed by tumor cells and mesothelial-associated fibronectin is a molecular 
event that contributes to the clearance process. In addition, we show that expression of 
talin I by tumor spheroids is required for !5"1 -mediated formation of traction force and 
mesothelial clearance. We found that interfering with the function of another fibronectin 
receptor, !v"3 integrin, did not affect spheroid–induced mesothelial clearance 
(Supplementary Figure 3.3C), suggesting that these receptors do not contribute to 
development of myosin contractility by OVCA433 spheroids that adhered to the 
mesothelial monolayer. This is consistent with previous experiments implicating !5"1 but 
not !v"3 integrins, in the development of contractility (25-27). Our data as well as earlier 
findings(3) show that the mesothelial cells retract in response to cancer cluster 
attachment. This raises an interesting question: how does the tumor induce retraction in 
the mesothelial cells? One possibility is that retraction is induced by the physical force 
of the spreading tumor cells pulling on the mesothelial cell’s associated ECM and 
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!provoking mesothelial cells migration away from the spheroid. Alternatively, the 
retraction of mesothelial cells could be provoked by a repulsive ligand presented on the 
tumor cells. In this study, we have shown that force produced by a spreading ovarian 
cancer cell cluster, via !5"1 integrin, myosin II and talin I, is important for mesothelial 
clearance. The evidence that ovarian cancer spheroids deficient in non-muscle myosin 
II were unable to sustain mesothelial clearance suggests that mere contact between 
tumor cells and mesothelial cells is not sufficient to induce retraction and migration of 
mesothelial cells and that a repulsive ligand presented by spheroid does not trigger 
retraction of the mesothelial cells. However, it is possible that interfering with myosin 
function also perturbs expression or activity of repulsive ligands present on tumor cell 
plasma membrane. Spheroid-induced mesothelial clearance was accompanied by 
disassembly of mesothelial cell matrix adhesion sites, indicating that force induced on 
the mesothelium by cancer spheroids initiates migratory response in individual 
mesothelial cells. In spheroid-induced matrix adhesion turnover experiments 
mesothelial cells that originated from peritoneal wall (LP9) exhibited much more 
dynamic integrin adhesion when compared to mesothelium isolated from lungs 
(MET5A) (compare movies 3.4A and 3.4B). This suggests that mesothelial cells 
covering different organs might elicit distinct migratory responses when contacting 
tumor spheroids.  
Earlier studies implicated mesothelial apoptosis as a mechanism of clearance as 
result of tumor cluster attachment (28). In our assays clearance of the mesothelium 
started about 30 minutes after spheroid attachment and was accompanied by migration 
of individual mesothelial cells from underneath of tumor spheroid. This observation 
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!argues that in our assay mesothelial cells respond to contacting tumor cells by 
activating migratory, but not apoptotic pathways. However it is possible that mesothelial 
cells that are “stuck” underneath the spheroid and cannot escape, undergo apoptosis. 
In patients with advanced disease ovarian tumor clusters predominantly implant into 
mesothelial lining of peritoneal cavity-associated organs. Invasive tumor implants are 
able to cross mesothelial layer and gain access to stroma beneath mesothelium (29). 
These observations suggest that the mesothelium presents a functional barrier to the 
spread and progression of ovarian tumors.  Hence, one would expect that progression 
toward invasive disease would be associated with alterations that enable the tumor cells 
to adhere to the mesothelium and brake mesothelial barrier by provoking mesothelial 
clearance. Our studies suggest that integrin-dependent activation of myosin contractility 
in tumor cells is required to perturb the mesothelial barrier. Therefore, our results 
suggest that acquisition of contractile phenotypes in ovarian tumor cells represents a 
step towards malignant progression.   
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!Materials and Methods: 
Cell Culture. All cells used in this study were cultured in a 1:1 ratio of Medium 199 
(GIBCO) and MCDB 105 (Cell Applications, INC) supplemented with 10% fetal bovine 
serum (GIBCO). Normal lung mesothelial cells were obtained from a benign pleural 
effusion from a patient with pneumothorax. These cells were immortalized by 
simultaneous inactivation of p53 and Rb through ectopic expression of SV40 T antigen 
and overexpression of human telomerase (fused to GFP) as described previously (30, 
31). In experiments involving a mixture of labeled and unlabeled mesothelial cells 
MET5A (human mesothelioma cells -ATTC) were used as a source of unlabeled cells. 
In focal adhesion tracking experiments, LP9s, a peritoneum-derived mesothelial cell line 
(Coriell Cell Repositories) was used. Primary lung mesothelial cells were under passage 
20. LP9 cells were used as passage under 10. MET5A mesothelial cells were used 
under passage 10 and these cells morphologically resembled primary lung mesothelilal 
cells that we used during the course of this experiment. OVCA433 and OVCAR5 
ovarian cancer cell lines were a generous gift from Dr. Dennis Slamon (University of 
California, Los Angeles). 
 
Spheroid-induced mesothelial clearance assay: The mesothelial cells were plated 
on glass-bottom dishes (Mat-TEK Corporation) coated with 5ug/ml of fibronectin 
(Sigma, USA) and/or collagen I (Sigma, USA). Cells were maintained in culture until 
confluent (48 hrs after plating). To generate spheroids, cells were dissociated by 
trypsinization, labeled with CMTX-red membrane dye (Molecular Probes), washed 2x 
with PBS, re-suspended in culture medium and plated on Poly-Hema-coated culture 
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!dishes (32). Spheroids were collected for experiments 36-48hrs later. The cell number 
varied from 100 to 500 cells per spheroid. OVCAR5 spheroids were generated in the 
presence of 10ug/ml of soluble bovine fibronectin to increase spheroid cohesion (33, 
34). In co-culture experiments, spheroids were added to a confluent mesothelial 
monolayer, allowed to attach for 60 minutes, and imaged for the indicated time. Only 
spheroids that remained attached during the experiment were used for quantification.  
 
Fibronectin labeling of mesothelial cells and quantification of fibronectin 
dissociation – 20 ug of rhodamine conjugated fibronectin (Cytoskeleton, USA) was 
added for a period of 24 hrs to a confluent monolayer of human lung mesothelial cells 
expressing GFP. To quantify fibronectin dissociation from the top of the mesothelial 
monolayer in the presence of cancer spheroids, we divided total fluorescent intensity of 
the fibronectin present beneath the cancer spheroid by the total intensity of GFP labeled 
mesothelial cells. 
 
Western blots and antibodies. Cells were lysed in 100 !l of RIPA buffer (50 mM 
HEPES pH 7.4, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 0.1 M NaCl, 1 
mM sodium orthovanadate, 0.1 M sodium pyrophosphate, 100 mM NaF and 1 mM 
PMSF). Lysates were clarified by centrifugation at 13,000 g for 10 minutes. Clarified 
lysates were boiled in 1x sample buffer (0.04 M Tris-HCl pH 6.8, 1% SDS, 1% "-
mercaptoethanol and 10% glycerol) for 10 minutes and resolved by SDS-PAGE. 
Proteins were transferred to Immobilon membranes (Whatman) and blocked with 5% 
BSA in PBS (140 mM NaCl, 0.27 mM KCl, 0.43 mM Na2HPO4#7H2O, 0.14 mM KH2PO4 
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!pH 7.3), 0.1% Tween 20, pH 7.2 for 1 hour at room temperature. Membranes were 
incubated overnight at 4°C with one of the following antibodies: anti-talin I polyclonal 
antibody (Cell Signalling, 1:1000), anti-actin monoclonal antibody (Sigma, 1:1000), anti-
myosin heavy chain IIA polyclonal antibody (Covance, 1:1000), anti-myosin heavy chain 
IIB polyclonal antibody (1:1000, Covance), anti-filamin A polyclonal antibody (1:1000, 
Cell Signaling), anti –cleaved caspase -3 polyclonal antibody (1:1000 , Cell Signaling) 
anti-!5 integrin polyclonal antibody (1:1000, Cell Signaling), anti-phosphorylated myosin 
light chain serine 18 polyclonal antibody ( 1:1000, Cell Signaling), or anti-myosin light 
chain polyclonal antibody (1:1000, Cell Signaling). Membranes were subsequently 
probed with secondary antibodies linked to horserasish peroxidase (HRP; Santa Cruz). 
Western blot membranes were developed using enhanced chemiluminescent substrate 
for detection of HRP (VWR). Western blot results were visualized using kodak film 
developer and an Epson 3000 scanner. OVCA433 spheroids were treated for 45 min in 
the presence of low serum medium (OPTIMEM) with the following cell adhesion 
blocking antibodies: anti-!5"1 (5ug/ml, BD Biosciences), anti-!2"1 (5ug/ml, BD 
Biosciences) integrins, anti-CD44 (5ug/ml, Sigma). We used non specific serum IgG 
(10ug/ml, Sigma ) in function blocking experiments. Treated spheroids were washed 
twice with PBS (CellGrow), re-suspended in culture medium and added to the 
mesothelial monolayer.  
 
shRNAs, siRNAs, cDNA plasmids and reagents. To attenuate the expression level of 
talin 1 and non-muscle myosin heavy chain IIA, OVCA433 cells were infected with 
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!lentiviruses lacking an shRNA sequence (pLKO) as a control, or plasmid containing talin 
1 (OpenBiosystems) 
(seq#1:CCGGGCAGTGAAAGATGTAGCCAAACTCGAGTTTGGCTACATCTTTCACTG
CTTTTTG 
seq#2:CCGGGCCTCAGATAATCTGGTGAAACTCGAGTTTCACCAGATTATCTGAGG
CTTTTTG 
seq#3:CCGGCGCATTGGCATCACCAATCATCTCGAGATGATTGGTGATGCCAATGC
GTTTTTG ) or non-muscle myosin IIA shRNA sequences (OpenBiosystems) 
seq#1:CCGGCGCATCAACTTTGATGTCAATCTCGAGATTGACATCAAAGTTGATGCG
TTTTTG 
seq#2:CCGGCGCATCAACTTTGATGTCAATCTCGAGATTGACATCAAAGTTGATGCG
TTTTT 
seq#3:CCGGGACAGCAATCTGTACCGCATTCTCGAGAATGCGGTACAGATTGCTGT
CTTTTT). Lentivirus-infected cells were selected for 72 hours in medium containing 
1ug/ml of puromycin (Dulbecco). To attenuate the expression level of non-muscle 
myosin IIB in OVCAR433 cells or talin 1 in OVCAR5 cells, we also used a pool of siRNA 
oligonucleotides against NMIIB or talin 1 respectively (Dharmacon). To ectopically 
express !5 integrin in OVCAR5 cells, we used a retroviral vector (pLZRS) encoding the 
human !5 integrin gene (generous gift from Dr.Erik Danen, The Netherlands Cancer 
Institute). Infected cells were selected in growth medium containing 600ug/ml G418 
(Dulbecco). Staurosporin was purchased from CalBiochem (USA). 
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!Live cell imaging.  
Spheroid-induced mesothelial clearance assay:  Imaging was performed using a Nikon 
Ti-E Inverted Motorized Widefield Fluorescence Microscope with integrated Perfect 
Focus System and low (20x-0.75 NA) magnification/NA DIC optics, Nikon halogen trans 
illuminator with 0.52 NA LWD condenser, Nikon fast (<100ms switching time) excitation 
and emission filter wheels, Sutter fast transmitted and epi-fluorescence light path Smart 
shutters, Nikon linear-encoded motorized stage, Hamamatsu ORCA-AG cooled CCD 
camera, custom-built microscope incubation chamber with temperature and CO2 
control, Nikon NIS-Elements AR software v3 and TMC vibration-isolation table 
 
Total Internal Reflection Fluorescence (TIRF) analysis: Mesothelial cell adhesion 
dynamics were visualized using Nikon Ti-E inverted microscope with integrated Perfect 
Focus System, Nikon 1.49 NA TIRF DIC optics (60x), Nikon halogen trans illuminator 
with 0.52 NA LWD and 0.85 NA Dry condenser, Nikon dual-port TIRF/Epi illuminator 
with motorized laser incident angle adjustment and motorized switching between TIRF 
and epi-illumination, Solamere laser launch with 100mW 491nm, 75mW 561nm and 
30mW 640nm solid state lasers with fiber-optic delivery system and 4-channel AOTF, 
Prior controller, Prior fast excitation and emission filter wheels, Prior fast transmitted 
and epi-fluorescence light path shutters, Prior linear-encoded motorized stage, 
Hamamatsu ImagEM 512x512 back-thinned electron multiplying cooled CCD camera, 
20/20 Technologies Bionomic Controller/ Stage heater insert, Molecular Devices 
MetaMorph v7.7 and TMC vibration-isolation table 
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!Analysis of the dynamics of rhodamine-labeled fibronectin: Imaging was performed 
using a Spinning Disk Confocal Microscope: Nikon Ti-E inverted motorized microscope 
equipped with integrated Perfect Focus System, Nikon Plan Apo 1.4 NA DIC optics 
(60x), Nikon halogen trans illuminator with 0.52 NA LWD and 0.85 NA Dry condenser, 
Yokogawa CSU-X1 spinning disk confocal head with internal motorized high speed 
emission filter wheel and Spectral Applied Research Borealis modification for increased 
light throughput and illumination homogeneity, Spectral Applied Research custom laser 
merge module (LMM-7) with AOTF and 100-200mW solid state 442nm, 491nm, 515nm, 
561nm, and 642 nm lasers, Semrock 405/488/561/647 and 442/514/647 dichroic 
mirrors, Prior ProScan II controller, Prior NanoScan piezo Z stage insert for high speed 
z-series, Prior fast transmitted and epi-fluorescence light path shutters, Hamamatsu 
ORCA-AG cooled CCD camera, custom built 37°C microscope incubator enclosure with 
5% CO2 delivery, Molecular Devices MetaMorph v7.7 and TMC vibration-isolation table. 
 
Quantification of mesothelial clearance and dissociation of fibronectin. To quantify 
mesothelial clearance, the non-fluorescent area in the GFP mesothelial monolayer was 
measured over time and divided by the initial area of the cancer spheroid. To quantify 
the dissociation of fibronectin from the mesothelial cells, the total fluorescence intensity 
of rhodamine-labeled fibronectin (enclosed within the area of the spheroid) was divided 
by the total fluorescent intensity of GFP-labeled mesothelial cells beneath the spheroid. 
Data was plotted as a point distribution using JMP8 statistical software. We used the 
non-parametric Mann-Whitney t-test to calculate statistical significance.* denotes  
p=0.05, ** denotes p =0.01, *** denotes p=0.001. 
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! 
Cancer spheroid adhesion assay. OVCA433 spheroids were co-cultured with 
mesothelial monolayers for five hours. Spheroids that did not adhere to the monolayer 
within this time were removed and re-plated on fibronectin and collagen I coated glass 
bottom dish for 60 minutes, the spheroids were counted. All spheroids that adhered to 
the mesothelial monolayer were counted. The number of spheroids adhered to the 
mesothelial monolayer plus the number of spheroids adhered to the matrix-coated dish 
represented the total number of spheroids. The percentage of spheroids adhered to the 
mesothelium was calculated by dividing the amount of spheroids attached to the 
mesothelium by the total number of spheroids (mesothelium + culture dish). 
 
Preparation of Polyacrylamide (PAA) Gel Substrates for Traction Force 
Microscopy (TFM). Fibronectin-coated PAA gels containing 0.2um fluorescent 
microspheres (Invitrogen) were prepared on glass-bottomed dishes as described 
previously (Wang and Pelham, 1998). In brief, the glass surfaces were incubated with 
0.1N NaOH and air dried. The surfaces were then subsequently incubated with 3-
aminopropyltrimethoxysilane (Sigma) and 0.5% glutaraldehyde (Sigma), and washed in 
distilled H2O between incubations. After drying, a drop of acrylamide/bis-acrylamide 
solution containing ammonium persulfate (BioRad), tetramethylethylenediamine 
(TEMED; Sigma) and 0.2um fluorescent microspheres was pipetted onto the modified 
glass surface. A coverslip was then placed over the droplets to ensure a flat gel surface 
after polymerization. Fibronectin was coupled to the PAA substrates via the bi-functional 
crosslinker sulfosuccinimidyl hexanoate (sulfo-SANPAH; Pierce). For traction force 
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!measurements of OvCar5 and OvCar5 cells overexpressing !5 integrin, gels with 
elastic moduli of approximately 10-20kPa were used.  
 
Traction Force Microscopy and Calculations of Traction Forces. 
Cells on PAA substrates were imaged with a multispectral multimode spinning disk 
confocal microscope consisting of a Nikon Ti-E inverted motorized microscope 
equipped with a custom built 37°C microscope incubator enclosure with 5% CO2 
delivery, an integrated Perfect Focus System, a 40x 0.95NA Plan Apo objective, a 
Yokogawa CSU-X1 spinning disk confocal head with internal motorized high speed 
emission filter wheel and Spectral Applied Research Borealis modification for increased 
light throughput and illumination homogeneity, and a Hamamatsu ORCA-AG cooled 
CCD camera. Images were acquired with MetaMorph software (MDS Analytical 
Technologies). Cells were trypsinized with 0.25% trypsin after imaging to obtain an 
image of unstrained bead positions as reference frames for analyses. Positions of 
fluorescent beads were extracted from image series and tracked using time-integrated 
cross-correlation tracking as described previously. Traction forces generated by the 
cells were determined using custom MatLab programs following the boundary element 
and Fourier transform traction cytometry methods described by Sabass et al (16). 
Square image blocks with a template size of 25pixels (= 4.1um) were centered on each 
reference bead position, identified as intensity maxima in the reference frame. Bead 
displacements were defined as the x-y-shift that maximizes the cross-correlation score 
of these image blocks in a corresponding region of the deformed bead image. To 
minimize false positive template matching, bead displacements with an insignificant 
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!maxima in the cross-correlation score function are rejected (35).Traction forces were 
reconstructed from the measured bead displacements using an implementation of the 
regularized Fast Fourier Traction Cytometry (FTTC)  method (36) provided by (16). For 
this study we regarded the PAA substrate as isotropic, linear elastic, infinite half-space, 
and thus applied the Boussinesq Green function. In order to solve the ill-posed inversion 
problem, we applied zero-order Tikhonov regularization (37). The regularization 
parameter ! has been determined using the L-curve method and we used the strain 
energy U , invested by the cell to deform the substrate, as a measure for cellular 
contractility (36) !
"
#= rdrurTU !!!!
!
)()(
2
1  
Here, T
!
 and u!  denote the measured displacement and reconstructed traction stress, 
respectively. To avoid possible boundary artifacts introduced by the FTTC algorithm 
(36) integration was performed over a hand drawn elliptical domain !
 
that just covered 
the whole footprint of the cell. Data was plotted as a point distribution using JMP8 
statistical software. We used the non-parametric Mann-Whitney t-test to calculate 
statistical significance.* -denotes  p=0.05 ** - denotes p =0.01 *** - denotes p=0.001. 
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Mesothelial Clearance Ability of Ovarian 
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Abstract: 
Metastatic dissemination of ovarian tumors involves the invasion of tumor cell 
clusters into the mesothelial cell lining of peritoneal cavity organs. We used an in 
vitro mesothelial clearance assay that models this initial step of ovarian cancer 
metastasis to determine the clearance ability of a large panel of both established 
and primary ovarian cancer cell lines. Comparison of the gene and protein 
expression profiles of clearance-competent and clearance-incompetent cell lines 
revealed that mesenchymal genes are enriched in cell lines that showed strong 
clearance activity, while epithelial genes are enriched in cell lines with weak or 
undetectable activity. Over-expression of the EMT-regulatory transcription factors 
SNAI1, TWIST1 and ZEB1 promoted mesothelial clearance in cell lines with 
weak activity, while knockdown of the EMT-regulatory transcription factors 
TWIST1 and ZEB1 attenuated mesothelial clearance in lines with strong activity. 
These findings provide important new insights into the mechanisms associated 
with metastatic progression of ovarian cancer.  
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Significance: 
The current treatment course for ovarian cancer involves cytoreductive surgery 
followed by platinum-taxane based chemotherapy. These treatments are 
insufficient because chemoresistant disease often recurs and advanced disease 
is often complicated by bowel obstruction. Our data suggest that inhibiting 
pathways that drive mesenchymal programs may suppress tumor cell invasion of 
peritoneal tissues and may be a useful treatment option in addition to existing 
therapies to prevent or partially thwart the development of late stage disease 
complications.  
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Introduction: 
Ovarian cancer has the highest mortality rate of all gynecological cancers and 
the fifth highest mortality rate of all cancers in the United States(1, 2). Because 
early disease is asymptomatic, ovarian cancer is rarely diagnosed until late 
stages, when the cancer has spread beyond the primary tumor site(3). Ovarian 
cancer metastasis involves detachment of tumor cells from the primary tumor site 
and attachment on the surface of other organs within the peritoneal cavity(4, 5), 
including the omentum, peritoneum, diaphragm, and small bowel mesentery(6).  
Generally, tumor nodules develop on the surface of the peritoneal organs and 
subsequently intercalate through the mesothelial lining into the underlying tissues.  
This can often lead to significant clinical complications, including bowel 
obstructions. 
 All of the organs within the peritoneal cavity are lined with a continuous 
monolayer of mesothelial cells(7-9). Electron micrograph studies of ovarian 
cancer nodules attached to peritoneal cavity organs revealed that mesothelial 
cells are absent from underneath the attached tumor mass(8-11). Interestingly, in 
vitro studies have shown that ovarian cancer cells are able to attach more firmly 
to extracellular matrix (ECM) components compared to either plastic culture 
dishes or mesothelial cell monolayers(12). Furthermore, attachment and invasion 
of ovarian cancer cells into a 3D collagen gel is delayed when the gel is covered 
with a mesothelial monolayer(13). These observations suggest that mesothelial 
cells can act as a protective barrier against ovarian cancer metastasis, and that 
mesothelial cells are excluded during processes leading to successful tumor cell 
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implantation on peritoneal tissue.  
Ovarian cancer cells can attach and spread on multiple ECM proteins, 
including collagen I, collagen IV, laminin, vitronectin and fibronectin; ! and " 
integrins, as well as CD44, have been shown to serve as tumor cell receptors for 
these ligands(10, 12, 14-22). While ovarian cancer cell adhesion and spreading 
on mesothelial monolayers has been well characterized, there has been much 
less focus on understanding the mechanisms associated with ovarian cancer cell 
invasion into and displacement of cells in the mesothelial monolayer. Several 
groups have examined the ability of single ovarian cancer cells to transverse 
through a mesothelial monolayer and found that inhibiting VCAM, a4-integrin, "1-
integrin, MMP-2, or MMP-9 could decrease the extent of invasion(22-24).  
Previously, we have shown that ovarian cancer multicellular spheroids are able 
to attach to and clear a hole in a mesothelial cell monolayer through an integrin- 
and force-dependent process involving !5 integrin, talin I and myosin II; inhibiting 
any of those molecules significantly decreases mesothelial clearance ability(25).  
In this paper, we sought to better understand the mechanisms by which 
ovarian cancer multicellular spheroids clear the mesothelial monolayer by 
characterizing the clearance abilities of a panel of 20 established ovarian cancer 
cell lines and 21 primary ovarian cancer cell samples.  Comparison of the gene 
and protein expression profiles of ovarian cancer spheroids that are competent or 
incompetent to clear mesothelial monolayers revealed distinct differences in the 
expression of mesenchymal and epithelial cell markers that correlated with 
clearance competency. Modulation of mesenchymal transcription factors to 
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promote or inhibit mesenchymal gene expression altered the clearance ability of 
the tumor cell lines. These studies provide important new insights into the 
mechanisms involved in mesothelial cell invasion.  
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Results: 
Differential Ability of Ovarian Cancer Spheroids to Clear a Mesothelial 
Monolayer: 
We have previously shown that OVCA433 ovarian cancer multicellular spheroids 
are able to attach to, intercalate into, and form a hole in a ZT mesothelial cell 
monolayer, while OVCAR5 ovarian cancer multicellular spheroids are unable to 
clear the monolayer(25). To explore the differences in gene and protein 
expression that distinguish clearance-competent ovarian cancer multicellular 
spheroids from clearance-incompetent spheroids, we first analyzed the ability of 
preformed multicellular spheroids from 20 different ovarian cancer cell lines to 
form a hole in GFP-expressing ZT mesothelial monolayers using time lapse 
video microscopy (Figure 4.1A).   
 After 8 hours of co-culture, clearance ability was scored. 11 ovarian 
cancer cell lines (ES2, CP70, OVCAR3, OVCA433, OV207, A2780, TOV112D, 
DOV13, OVCA432, HEYC2, OV2008) were able to clear the mesothelial 
monolayer, three (OVSAHO, C13, OAW28) cleared weakly, and six (PE06, 
CAOV3, OVCA429, EFO21, MCAS, RMG1) did not clear (FIGURE 4.1B, 
Supplementary Figure 4.1, Supplementary Movie 4.). These results indicate that 
there is a continuum of clearance abilities among ovarian cancer spheroids.  The 
cell lines with a normalized clearance area greater than one will be referred to as 
clearance-competent, while the cell lines with a normalized clearance area less 
than one will be considered clearance-incompetent. 
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Ovarian Cancer Spheroid Clearance Ability Correlates with the Expression 
of Mesenchymal and Epithelial Markers: 
To explore differences between cell lines with distinct clearance competencies, 
relative gene expression was measured in the 2O ovarian cancer cell lines using 
an Agilent Human 44K expression microarray. 1426 unique genes were identified 
that distinguished the clearance-competent cell lines from the clearance-
incompetent cell lines (p<0.05, Supplementary Table 4.1). Enrichment analysis 
demonstrated that this set was enriched for genes in the GeneGo Pathway 
Maps: “TGF! dependent induction of Epithelial-to-Mesenchymal Transition 
(EMT) via SMADs” and “regulation of epithelial-to-mesenchymal transition” 
(p<7.37X10-5 and p<5.69x10-4 respectively, GeneGo). To further validate this 
pathway enrichment, we analyzed the overlap between our set of differentially 
expressed genes and an EMT signature consisting of a 159 gene- EMT core 
signature (26) and 6 established EMT transcriptional regulators (TWIST1, 
TWIST2, ZEB2, SNAI1, SLUG, OVOL1)(27). The genes differentially regulated in 
clearance competent cell lines were 2.4-fold enriched for genes in the core EMT 
signature (p=1.94X10-8, Figure 4.1C, fold enrichment is defined as the observed 
frequency divided by the expected frequency). Figure 4.1C shows that genes 
characteristic of a mesenchymal phenotype are enriched in the clearance-
competent ovarian cancer cell lines, while genes characteristic of an epithelial 
phenotype are enriched in the clearance-incompetent cell lines. Interestingly, 
OVCA432, HEYC2 and OV2008 cells, which exhibited borderline clearance 
activity, expressed the weakest mesenchymal signature.   
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Protein expression of the epithelial marker, E-cadherin, and the 
mesenchymal marker, vimentin, were confirmed in the ovarian cancer cell lines 
by western blotting (Figure 4.1D). Consistent with the microarray data, average 
E-cadherin protein expression was lower in the clearance-competent cell lines 
compared to the clearance-incompetent cell lines (Figure 4.1E), whereas, 
average vimentin protein expression was higher in the clearance-competent cell 
lines compared to the clearance-incompetent cell lines (Figure 4.1F). Taken 
together, these data suggest that clearance-competent cell lines are enriched for 
mesenchymal markers, while clearance-incompetent cells are enriched for 
epithelial markers.  
 
Over-expression of TWIST1, ZEB1 or SNAI1 Promotes Mesothelial 
Clearance:  
To determine if mesenchymal gene programs functionally regulate mesothelial 
clearance, we modulated the expression of several EMT transcription factors in 
the ovarian cancer cell lines and measured the effects on clearance ability. First, 
we examined whether over-expression of the EMT transcription factors TWIST1, 
ZEB1, and SNAI1 in a clearance-incompetent cell line (MCAS) could promote 
clearance ability. TWIST1 and ZEB1 were chosen because their expression 
correlated significantly with clearance ability (Figure 4.1C). SNAI1 was chosen 
because it is known to be a strong inducer of EMT(28).   
We were unable to establish stable lines of MCAS cells overexpressing 
TWIST1, ZEB1, and SNAI1, most likely because EMT-inducing transcription 
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factors can suppress proliferation when overexpressed in tumor cell lines(29-31); 
therefore, we inducibly over-expressed these genes in the clearance-
incompetent MCAS cell line. Expression was induced for 7-14 days by 
supplementing the growth medium with 20nM 4-hydroxytamoxifen (OHT) (for the 
TWIST1 and SNAI1 vectors) or 1µg/ml Doxycycline (for the ZEB1 vector) every 
other day. Induction of SNAI1, ZEB1 or TWIST1 resulted in a 72-fold, 10-fold, or 
3.6-fold increase in SNAI1, ZEB1 or TWIST1 mRNA, respectively (Figure 4.2A-
C). The expression of several EMT markers was measured by qPCR in the 
SNAI1, ZEB1, and TWIST1-overexpressing cells. These markers were chosen 
because they were both differentially expressed in the clearance-competent and 
clearance-incompetent cell lines and part of Taube core EMT signature (Figure 
4.1C). SNAI1 overexpression produced the most dramatic change in marker 
expression, inducing the mesenchymal markers TSHZ1, COL5A and FBN1 and 
suppressing the epithelial markers E-cadherin, MYO5C, KRT18, KRT8, ANXA3 
and ST14 (Figure 4.2D). ZEB1 overexpression induced the expression of the 
mesenchymal markers TSHZ1 and FBN1, and decreased the expression of E-
cadherin, while the expression of other epithelial markers was unchanged (Figure 
4.2E). TWIST1 overexpression induced the expression of the mesenchymal 
marker N-cadherin and decreased the expression of the epithelial markers E-
cadherin and keratin 8 (Figure 4.2F). Furthermore, phase-contrast imaging of 
attached cells showed that while control MCAS cells grouped in small clusters, 
TWIST1, ZEB1 and SNAI1 overexpressing MCAS cells were more discohesive.  
In addition, the SNAI1 overexpressing cells were elongated compared to control 
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cells (FIGURE 4.2G). Failure to see a more dramatic switch in the TWIST1 and 
ZEB1 overexpressing cells (low fold change, only a small number of cells 
phenotypically different, Figure 4.2B,C and G) could reflect the fact that EMT 
transcription factor overexpression suppresses proliferation (32) suggesting that 
only a small number of cells in the population can sustain the EMT switch.    
Mesothelial Clearance analysis revealed that SNAI1, ZEB1 or TWIST1 
over-expression significantly increased the mesothelial clearance ability of MCAS 
spheroids compared to both un-transfected and un-induced controls (Figure 4.2H, 
2I and Supplementary Figure 4.2) and the degree of increase in clearance ability 
correlated with the strength of epithelial and mesenchymal marker change 
(Figure 4.2D-F). Taken together, these results suggest that the over-expression 
of EMT transcription factors can increase mesothelial cell clearance ability. 
Interestingly, each transcription factor was associated with changes in a different 
set of mediators. This could suggest that several different mediators are involved 
or alternatively that mediators in addition to those assessed by QPCR are critical. 
 
Knockdown of TWIST1 and ZEB1 Reduces Mesothelial Clearance: 
To further evaluate the regulation of clearance by transcription factors that 
modulate EMT, we decreased the expression of EMT transcription factors in 
clearance-competent cell lines. Since TWIST1, ZEB1 and ZEB2 expression 
correlated significantly with clearance ability (Figure 4.1C), we knocked down the 
expression of TWIST and ZEB transcription factor family members in OVCA433 
cells. Knockdown of ZEB1, TWIST1, ZEB2 and TWIST2 genes with siRNA 
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SMARTpools significantly decreased their respective mRNA expression levels as 
measured by qPCR 48 hours after treatment (Figure 4.3A-D). Western blot 
analysis revealed that E-cadherin protein expression was increased in both the 
TWIST1 and ZEB1 siRNA knockdown cells, while vimentin protein expression 
was unchanged (Figure 4.3I).  qPCR analysis of other EMT markers revealed 
that ZEB1 knockdown produced the most dramatic effect, consistent with the 
strong level of E-cadherin protein expression; EXPH5, KRT18, KRT8 and ANXA3 
mRNAs were significantly increased in the ZEB1 knockdown cells, while COL5A2 
mRNA was significantly decreased (Figure 4.3E). The effects of TWIST 1 and 
ZEB2 knockdown on EMT marker gene expression were less significant  (Figure 
4.3F and G), and there was no significant marker expression change in TWIST2 
knockdown cells (Figure 4.3H). The weak effects on gene expression, particularly 
the lack of decrease of vimentin and other mesenchymal markers, could reflect 
the need for a longer knockdown time to reverse the expression of the 
mesenchymal gene program (33, 34). Nevertheless, knockdown of TWIST1 and 
ZEB1 by siRNA in OVCA433 cells enhanced E-cadherin expression and several 
other epithelial markers; therefore we examined the effects of knockdown on 
mesothelial clearance.   
The TWIST1, TWIST2 and ZEB1 siRNA SMARTpools significantly 
decreased mesothelial clearance while the ZEB2 SMARTpools did not (Figure 
4.3J). To validate these findings, we tested the individual siRNAs that comprised 
the TWIST1, ZEB1, and TWIST2 SMARTpools for clearance inhibition; the 
reduction in clearance was consistent overall with the extent of knockdown for 
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TWIST1 and ZEB1, but not TWIST 2 (Supplementary Figure 4.3). Finally, ZEB1 
expression was knocked down using shRNA-expressing lentiviral vectors. Three 
of the four hairpins significantly decreased ZEB1 mRNA expression (Figure 4.3K). 
Western blot analysis revealed that E-cadherin expression was increased and 
vimentin expression was decreased in the cells with reduced ZEB1 expression 
(Figure 4.3L). While there was variation in the extent of up- or down-regulation of 
EMT markers, overall the expression of mesenchymal genes was decreased and 
the expression of epithelial genes were increased in the cells with significant 
ZEB1 down-regulation (Figure 4.3M-P). Consistent with the clearance results for 
the siRNA knockdown cells, ZEB1 down-regulation by shRNA significantly 
decreased mesothelial clearance (Figure 4.3Q). Knockdown of TWIST1 in 
OVCA433 cells using shRNA-expressing lentiviral vectors decreased mesothelial 
clearance and the expression of mesenchymal markers, and the decrease in 
clearance correlated with the extent of knockdown (Supplementary Figure 4.4). 
siRNA knockdown of TWIST1 and ZEB1 in a second cell line, OVCA432, also 
significantly decreased mesothelial clearance (Supplementary Figure 4.5). Taken 
together, these results suggest that TWIST1 and ZEB1 are required for efficient 
mesothelial clearance in OVCA433 and OVCA432 cell lines and that reduction in 
these transcription factors increases the epithelial phenotype of ovarian tumor 
cells lines.  
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Vimentin Regulates Mesothelial Clearance Ability: 
Vimentin, an intermediate filament protein and downstream effector of EMT 
transcription factors (27) is enriched in the clearance-competent ovarian cancer 
cell lines (Figure 4.1). Because vimentin expression has been implicated in cell 
motility(35), we wanted to determine if vimentin could also regulate mesothelial 
clearance. Vimentin expression was reduced in OVCA433 cells using siRNA 
SMARTpools, causing a down-regulation of vimentin protein expression and 
significantly decreased mesothelial clearance. (Figure 4.3R and 3S, respectively). 
Furthermore, knockdown of vimentin using shRNA hairpins significantly 
decreased mesothelial clearance, as well (Supplementary Figure 4.6). In support 
of this data, vimentin knockdown in CP70 cells also decreased mesothelial 
clearance (Supplementary Figure 4.7). 
 
Differential Clearance Ability in Primary Ovarian Cancer Cells from the 
Ascites Fluid of Ovarian Cancer Patients correlates with the Expression of 
E-cadherin and Vimentin:  
To determine if similar correlations between clearance activity and epithelial or 
mesenchymal phenotypes could be observed in primary ovarian cancer cell 
samples, we examined mesothelial clearance activity of primary serous papillary 
ovarian tumor cells derived from ascites fluid of 21 patients with high-grade 
serous ovarian cancer (DF9, DF14, DF24, DF29, DF43, DF59, DF68, DF106, 
DF118, DF141, DF143, DF147, DF155, DF160, DF163, DF164, DF166, DF168, 
DF172, DF173, DF176). This was greatly facilitated by the development of WIT-
112
OC medium, which maintains the viability of primary tumor cells. Minimally 
processed frozen vials of primary ovarian cancer cells were plated on tissue 
culture plastic for 48 hours. The attached cells were trypsinized and divided into 
three aliquots. One aliquot was plated on untreated tissue culture plates for 24 
hours and then lysed for Western Blot and Reverse Phase Protein Array (RPPA) 
analysis to measure the expression of epithelial and mesenchymal markers.  A 
second aliquot was plated on poly-HEMA coated culture dishes and grown in 
suspension for 24 hours before being lysed for marker analysis. The third aliquot 
was plated, 100 cells per well, in 96-well poly-HEMA-coated culture dishes to 
form multicellular spheroids and after 16 hours in suspension the spheroids were 
analyzed for clearance activity (Figure 4.4A). After eight hours of co-culture in the 
Mesothelial Clearance assay, 14 of the primary cell lines were clearance-
competent (normalized clearance area >1), while seven of the primary cell 
populations were clearance-incompetent (normalized clearance area <1)(Figure 
4.4B, Supplementary Figure 4.8, Supplementary Movie 4.2). Cells from several 
representative clearance competent DF cell populations (DF143, 164, and 163) 
were stained for Pax8 (a mullerian marker expressed by serous papillary ovarian 
tumors (36-39)) after spreading on mesothelial monolayers or glass; all of these 
lines expressed nuclear Pax8, confirming the ovarian carcinoma origin of 
clearance-competent cells (Supplementary Figure 4.9). Quantification of the 
levels of expression of E-cadherin and vimentin from Western blot analyses 
revealed a significant enrichment of E-cadherin in the clearance-incompetent DF 
lines, while vimentin was enriched in the clearance-competent DF tumor cells 
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(Figure 4.4C, D and E). These results strongly support the findings from the 
established ovarian cancer cell lines. 
We also examined the expression of E-cadherin and vimentin by 
immunofluorescent staining of sections from the cell blocks of the ascitic fluid 
from which the DF cell populations were derived. Figure 4.4F shows 
representative images of DF147, DF176, DF164 and DF143 tumor samples. 
Consistent with the western blot data, ovarian cancer cells from DF174 and 
DF176, two clearance-incompetent cell populations, were positive for E-cadherin, 
but not vimentin, while ovarian cancer cells from DF164, a clearance-competent 
line, strongly stain for vimentin and only weakly stain for E-cadherin. The stromal 
and hematopoietic cells in samples DF147 and DF164 express high levels of 
vimentin. These cells were likely cleared by the filtration step that was used for 
processing the ascitic fluid samples since there were low levels of vimentin in the 
cultured DF147 cells.  
 
Protein Expression Profile of Clearance-Competent and Clearance-
Incompetent Primary Ovarian Cancer Spheroids 
To better characterize the primary tumor samples, the expression levels of 
151 proteins and phosphoproteins representing major signaling pathways and 
some EMT marker proteins were measured in the 21 primary ovarian cancer cell 
populations using reverse phase protein arrays. To identify the proteins that are 
differentially expressed between primary cell populations with different levels of 
clearance activity, a multiple linear regression model was constructed using the 
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normalized clearance area data from the mesothelial clearance assay and the 
relative protein expression data from the RPPA analysis. In this analysis, only 
cell populations with a clearance-competent value >2.5 or a clearance-
incompetent value <1.0 were used. Figure 4.5A shows a heatmap with the 
antibody probes that have a significant linear relationship (p<0.05) with 
normalized clearance area. Consistent with the above findings, epithelial proteins, 
including E-cadherin, claudin 7, and HER3 are enriched in the primary cell 
populations that display the weakest clearance activity. Mesenchymal markers 
are not well represented in the list of antibodies available for RPPA analysis, so 
the expression of mesenchymal proteins could not be evaluated in this analysis. 
Interestingly however, YAP, which induces EMT when over-expressed in 
mammary epithelial cells(40), is strongly correlated with clearance competent cell 
populations.  eEF2 and eEEF2 kinase are also enriched in this population.   
The RPPA data described above was derived from primary ovarian cancer 
cells that were able to initially attach to a cell culture dish 48 hours after thawing 
from a stock vial. For several of the primary cell populations, a proportion of the 
cells were unable to attach to the culture dish after 48 hours. These nonadherent 
cells did not display activity in the mesothelial clearance assay (data not shown).  
Interestingly, the protein expression profiles of the non-attached cell populations 
derived from the clearance-competent cell populations are strikingly similar to the 
protein expression profiles of the clearance-incompetent DF populations (being 
enriched for epithelial markers and other proteins in this signature), and clearly 
distinguished from the cell populations from the same tumor that initially attached 
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to tissue culture plates (Figure 4.5B). In contrast, for those tumors in which the 
attached cells were classified as clearance-incompetent, the protein expression 
pattern of the unattached population and attached population of the same cell 
line were indistinguishable (Figure 4.5B). 
Figure 4.5C shows histology sections from the DF155 primary tumor (one 
of the tumors in which the ascites samples displayed heterogeneous cell 
populations with differential abilities to attach to culture plates) stained for both E-
cadherin and vimentin. Both E-cadherin and vimentin were focally expressed in 
some, but not all, of the ovarian cancer cells. E-cadherin and vimentin expression 
was almost entirely mutually exclusive (see arrows), supporting the existence of 
two distinct tumor populations. Taken together, these results suggest that 
primary ovarian cancer effusions contain a heterogeneous population of cells 
with differential ability to clear monolayers and cells that exhibit mesenchymal 
markers display the strongest clearance activity.   
 
Mesenchymal Gene Signature in Patients with Epithelial Ovarian Cancer 
We compared the gene expression profiles of ovarian tumors in the Tothill data 
set to the EMT signature defined in Figure 4.1 and found that 21% (59/285) of 
the tumors expressed the EMT signature (Figure 4.6A). This group displayed 
significantly reduced overall and relapse-free survival compared to all other 
patients in this study (Figure 4.6B). This analysis indicates that there is a specific 
subtype of epithelial ovarian cancers that displays mesenchymal characteristics 
and mesenchymal characteristics correlate with reduced survival.  
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Discussion: 
In this study, we conducted a comprehensive analysis of the gene and protein 
expression profiles of ovarian cancer spheroids with differential mesothelial 
clearance abilities. Using 20 ovarian tumor cell lines, we identified a gene 
expression profile that correlated with mesothelial clearance activity. The 
expression of genes in an EMT core signature was enriched in the cell lines that 
showed strong mesothelial clearance activity compared to those with weak or 
undetectable activity. This pattern was validated in primary tumor cell cultures 
using several EMT markers; vimentin (a mesenchymal marker) was expressed at 
higher levels in primary cells with high clearance activity, while E-cadherin, 
claudin 7, and HER3 (epithelial markers) expression was increased in primary 
cells with low clearance activity. These correlations were detected even in 
subpopulations within individual primary tumor cell samples. Thus, these studies 
provide insights into the molecular features that correlate with mesothelial 
invasive ability. 
EMT is defined as a process in which apico-basal-polarized, immotile, 
epithelial cells that are attached together by cell-cell junctions are converted to 
planar-polarized, migratory, mesenchymal-like cells with weaker cell-cell 
adhesion. EMT occurs throughout development, most notably during gastrulation 
when cells in a single germ layer migrate to produce three germ layers and 
during vertebrate nervous system development when epithelial cells located near 
the dorsal midline of the neural tube are converted to mesenchymal cells that 
migrate to distinct regions within the embryo(41). It has been proposed that 
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cancer cells hijack EMT transcriptional programs to dissociate from the primary 
tumor, intravasate and extravasate through the blood or lymphatic systems to 
colonize distant sites(27). Ovarian cancer cells do not face these barriers to 
metastasize to the peritoneum; instead, they are displaced from primary tumors 
directly into the peritoneal cavity, where they can transit to other peritoneal 
tissues and then invade through the mesothelial lining to colonize new sites.  
Our studies indicate that EMT transcription factors promote mesothelial 
invasion by ovarian cancer cells. Over-expression of SNAI1, ZEB1 or TWIST1 in 
clearance-incompetent cell lines significantly increased mesothelial clearance 
ability. Conversely, inhibition of TWIST1 and ZEB1 in clearance competent 
ovarian cancer cell lines significantly decreased mesothelial clearance.  A recent 
study reported a correlation between expression of CD157, an ectoenzyme 
regulating leukocyte diapedesis, expression of mesenchymal markers, and 
enhanced mesothelial invasion in ovarian cancer cells(42).  Previous reports 
have used Boyden chamber migration assays to examine the role of EMT 
transcription factors in modulating other phenotypic aspects of the invasive 
behavior of ovarian tumor cell lines. For example, down-regulation of SNAI1 or 
TWIST1 expression in ES2 or HEY cells, respectively, suppressed invasion 
through Matrigel(43, 44). Similar differences in invasive behavior caused by EMT 
transcription factor modulation have been described in many other tumor cell 
lineages (reviewed in(45, 46)).  
 Recently, Kwon et al. correlated the ability of ovarian cancer spheroids to 
remodel extracellular matrices with the expression of epithelial and mesenchymal 
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markers(47).  They divided the cell lines into two groups: one that remodeled the 
ECM by degradation and one that remodeled the ECM by ROCK-mediated 
reorganization. The authors suggested that ovarian cancer cells could use two 
distinct strategies to remodel ECM during ovarian cancer metastasis. 
Interestingly, the cell lines that employed ROCK-mediated reorganization of the 
ECM expressed mesenchymal markers, including N-cadherin and vimentin, while 
the cell lines that remodeled the ECM via degradation expressed epithelial 
markers, including E-cadherin and pan-keratin. Our results suggest that only 
mesenchymal-like cells are able to clear the mesothelial monolayer and gain 
access to the underlying ECM. Therefore, in the context of metastasis, the ECM 
would be remodeled by ROCK-mediated reorganization by the mesenchymal-like 
cells. The ECM under the mesothelial monolayers would only be degraded via 
proteolysis if the invasive mesenchymal-like cells revert to an epithelial-like 
phenotype after implantation.  
 While we have shown that tumor cells that express genes associated with 
a mesenchymal program display more effective mesothelial clearance, in vitro, 
the contribution of these cells to ovarian cancer progression remains unclear. 
Studies have found that higher SNAI1 or TWIST expression in primary ovarian 
carcinomas, ovarian cancer effusions and metastases are associated with 
shorter overall and progression free survival(48-52). In addition, the expression 
of SNAI1 and TWIST1 are significantly higher in later stage (III and IV) compared 
to early stage ovarian tumors(48, 53). Consistently, increased expression of E-
cadherin is associated with better survival, while loss of E-cadherin expression is 
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associated with poor survival in several studies(50, 54-56). 
Tothill et al. used gene-expression profiling to characterize 285 well-
annotated serous and endometrioid invasive ovarian, fallopian tube, and 
peritoneal cancers and defined six subgroups with distinct molecular and 
histopathologic characteristics(57). One subgroup expressed genes associated 
with mesenchymal development (including increased expression of homeobox 
genes, WNT/h-catenin pathway components, and N- and P-cadherin). 
Interestingly, this subgroup displayed poorer overall survival than four of the five 
other subgroups. When we compared the gene expression profiles of the ovarian 
tumors in the Tothill study to the clearance-associated EMT signature defined in 
Figure 4.1, we found that 21% (59/285) of the tumors expressed this EMT 
signature (Figure 4.6). This group displayed significantly reduced overall and 
relapse-free survival compared to all other patients in this study (Figure 4.6). The 
decreased survival in this tumor subgroup may be due, at least in part, to the 
increased ability of these cells to invade into the mesothelial lining of peritoneal 
cavity organs. However, given that ovarian tumors show intratumoral 
heterogeneity with respect to epithelial and mesenchymal markers (as detected 
in tumor DF155 in our study), analyses involving RNA or protein expression of 
the total population of cells may mask the existence of mesenchymal cells that 
could contribute to mesothelial clearance.  It remains to be established whether 
inhibitors that block intercalation will be useful clinically to prevent new 
metastases, and their associated complications, following surgical debulking of 
peritoneal masses.   
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Our study provides insight into the molecular mechanisms that mediate 
mesothelial clearance by ovarian cancer multicellular spheroids. We have shown 
that ovarian cancer spheroids that display mesenchymal characteristics are more 
efficient at clearing a mesothelial monolayer. Furthermore, we found 
heterogeneity with respect to the expression of mesenchymal markers and 
competence for mesothelial clearance in primary tumor populations. These 
studies raise the possibility that inhibition of the mesenchymal program could 
reduce seeding of new metastatic lesions following surgical debulking. 
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Methods: 
Cell Culture: 
Established Cell Lines. 
All of the established ovarian cancer cell lines as well as the ZT mesothelial cells 
were cultured in a 1:1 ratio of medium MCDB 105 (Cell Applications, INC) and 
Medium 199 (GIBCO) supplemented with 10% FBS (GIBCO) and 5% pen-strep. 
The established ovarian cancer cell lines were a gift from Dr. Dennis Slamon 
(University of California, Los Angeles). ZT mesothelial cells were obtained from a 
benign pleural effusion. These cells were immortalized by ectopic expression of 
SV40 T antigen and over-expression of human telomerase (fused to GFP) as 
previously described. (58, 59).  
 
Primary Tumor Cells. 
With institutional review board approval, primary ovarian carcinoma cells (DF 
lines) were isolated directly from peritoneal paracentesis of patients with 
advanced-stage ovarian cancer at the time of initial cytoreductive surgery, as 
previously described(60, 61). Red blood cells were lysed as previously 
described(62). Only samples that were >80% pure tumor cells were used. In 
cases where there was more heterogeneity, the samples were enriched for tumor 
cells by filtration using a 40-µm nylon cell strainer (BD Falcon, San Jose, CA) to 
isolate tumor cell spheres. Tumor cells were frozen after isolation and aliquots 
were thawed and cultured in WIT-OC medium(63) as needed for the experiments 
described.  
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Mesothelial Clearance Assay: 
Preparation of Spheroids and Mesothelial Monolayer. The mesothelial clearance 
assay was performed as previously described(25) with minor alterations. Briefly, 
to generate multicellular spheroids, ovarian cancer cells were dissociated by 
trypsinization, re-suspended in cell culture medium and counted. 100 cells per 
well were plated in poly-HEMA coated 96-well round bottom plates (Corning) and 
the plates were incubated at 37°C for 16 hours to promote spheroid formation. 
Concurrently, 5,000 ZT mesothelial cells per well were plated on fibronectin 
(5ug/ml, Sigma)-coated 384 well glass-bottom culture dishes (Corning). The 
mesothelial cells were incubated at 37°C for 16 hours to form confluent 
monolayers. After the 16-hour incubations, the ovarian cancer multicellular 
spheroids were transferred to the wells containing the mesothelial monolayers.  
 
Live Cell Imaging.  
Imaging was performed using a Nikon Ti-E Inverted Motorized Widefield 
Fluorescence Microscope with integrated Perfect Focus System and low (20x-
0.75 NA) magnification/NA DIC optics, Nikon halogen trans illuminator with 0.52 
NA LWD condenser, Nikon fast (<100ms switching time) excitation and emission 
filter wheels, Sutter fast transmitted and epi-fluorescence light path Smart 
shutters, Nikon linear-encoded motorized stage, Hamamatsu ORCA-AG cooled 
CCD camera, custom-built microscope incubation chamber with temperature and 
CO2 control, Nikon NIS Elements AR software v3 and TMC vibration-isolation 
table. Over 20 spheroids were imaged per condition. Phase and GFP images 
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were captured every 10 minutes for 8 hours.  
 
Quantification of Mesothelial Clearance Area. The non-fluorescent area, created 
by the invading spheroid, in the GFP mesothelial monolayer images was 
measured at eight hours and divided by the initial area of the cancer spheroid at 
time zero. All measurements were taken using Nikon NIS Elements software.  
 
Quantification of Percent Hole Formation. For each condition, after eight hours of 
co-incubation, the number of positions with a mesothelial clearance area >1 were 
counted, divided by the total number of positions, and multiplied by 100.  
 
Microarray Analysis: 
Microarray hybridizations were performed in the ovarian cell lines at baseline 
using the Agilent Human 44K array chip. Briefly, cells were grown to log phase 
and then RNA was extracted using the RNeasy Kit (Qiagen, Valencia, CA, USA). 
The purified RNA was eluted in 30-60 µl diethylpyrocarbonate (DEPC) water and 
the quantity of RNA was measured by spectral analysis using the Nanodrop 
Spectrophotometer (NanoDrop Products, Wilmington, DE, USA). RNA quality 
was determined by separation of the RNA via capillary electrophoresis using the 
Agilent 2000 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). 
Characterization of individual ovarian cancer cell line transcripts was performed 
by comparison with a mixed reference cRNA pool consisting of equal amounts of 
RNA from 40 ovarian cancer cell lines and was conducted on a single slide in 
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which the cell line mixture RNA was labeled with cyanine-3 and RNA from the 
individual cell line was labeled with cyanine-5. Microarray slides were read using 
an Agilent Scanner and the Agilent Feature Extraction software version 7.5 was 
used to calculate gene expression values. Data was pre-filtered using a p-value 
threshold of p<0.01 in at least one cell line and differentially expressed genes 
were identified using the limma package of bioConductor R and a p-value 
threshold of 0.05.  
Enrichment was assessed in two ways: 1) differentially expressed genes 
were assessed for enrichment of GeneGO categories using GeneGO software 
(http://www.genego.com). 2) The differentially expressed genes were merged to 
an EMT signature consisting of the Taube EMT core signature(26) and 6 
additional transcription factors 
(‘SNAI1','SNAI2','ZEB2','TWIST1','TWIST2','OVOL1'). The background 
population set was the 15,900 unique genes after pre-filtering the ovarian cell line 
data. Enrichment p-values were calculated with hypergeometric distribution 
implemented in the phyper function in R.  Fold enrichment was defined as the 
observed frequency divided by the expected frequency. Hierarchical cluster 
diagrams were built using a Pearson uncentered distance measure under 
average linkage rules in Cluster (v.3.0) and visualized in Java Tree View (v1.1.0). 
 
Survival Analysis: 
The EMT signature was merged to the Tothill data downloaded from GEO 
(GSE9891)(57) using Affymetrix gene identifiers.  In order to deal with multiple 
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probes per gene, the probe with the highest variance was selected.  Patients 
were divided into two groups based on correlation or lack of correlation with the 
EMT signature; samples with the EMT signature were defined as Spearman ! 
=>.295 (p<0.05). Kaplan-Meier curves were generated using the survival 
package in R.  Log Rank p-values were computed with the survdiff function. 
 
Western Blot Analysis: 
Cells were lysed in RIPA buffer (50mM HEPES pH 7.4, 1% Triton X-100, 1% 
sodium deoxycholate, 0.1% SDS, 0.1M NaCl, 1mM sodium orthovanadate, 0.1M 
sodium pyrophosphate, 100mM NaF and 1mM PMSF). Lysates were clarified by 
centrifugation at 13,000g for 10 minutes at 4°C, protein concentration was 
quantified using the BCA assay (Pierce) and absorbance was read on a BioTEK 
Micro-Volume Spectrophotometer System (Epoch). 15ug lysates were boiled in 
1x sample buffer (0.04M Tris-HCl pH 6.8, 1% SDS, 1% !-mercaptoethanol and 
10% glycerol) for 10 minutes and resolved by SDS-PAGE. Proteins were 
transferred to Immobilon membranes (Whatman) and blocked with 5% BSA in 
PBS (140mM NaCl, 0.27mM KCl, 0.43mM Na2HPO4, 0.14mM KH2PO4 pH 7.3) 
for 30 minutes at room temperature. Membranes were incubated overnight at 
4°C with one or more of the following antibodies: anti-E-cadherin monoclonal 
antibody (1:1000, BD), anti-vimentin polyclonal antibody (1:1000, Cell Signaling), 
anti-GAPDH polyclonal antibody (1:20000, Abcam), or anti-tubulin polyclonal 
antibody (1:20000, Abcam). Membranes were then probed with secondary 
antibodies linked to horseradish peroxidase (HRP, 1:5000, Santa Cruz) or 
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secondary antibodies linked to fluorophores (1:5000, LI-COR) Western Blot 
membranes incubated with HRP were developed using an enhanced 
chemiluminescent substrate (VWR) and visualized using a Kodak film developer 
and an Epson 3000 scanner. Fluorophore treated Western Blot membranes were 
visualized using the Odyssey Imaging System (LI-COR Biosciences). Protein 
expression levels were quantified from the Western Blot membranes visualized 
using the Odyssey imaging system by measuring the mean pixel density of the 
band in question, using Image J software, and dividing by the mean pixel density 
of the corresponding loading control band.  
 
cDNA plasmids, siRNAs, shRNAs: 
To ectopically express TWIST1 or SNAI1, the retroviral vector (pWZL Blast ER) 
encoding the genes for TWIST1 or SNAI1, were transfected into MCAS and 
RMG1 ovarian cancer cells (Addgene plasmids 18799 and 18798, respectively). 
Cells were selected in 50ug/ml Blasticidin and induced with 20nM 4-OHT for 7 
day. siRNA SMARTpools against TWIST1, TWIST2, ZEB1, ZEB2, vimentin, and 
E-cadherin were used to attenuate the expression of the corresponding genes 
(Dharmacon). Lentiviruses lacking an shRNA sequence (pLKO) as a control, or 
plasmids containing TWIST1 hairpins (OpenBiosystems; G11 seq: 5'-CCGG-
CGCCTTCTCGGTCTGGAGGAT-CTCGAG-ATCCTCCAGACCGAGAAGGCG-
TTTTT-3', G12 seq: 5'-CCGG-TCCGCAGTCTTACGAGGAGCT-CTCGAG-
AGCTCCTCGTAAGACTGCGGA-TTTTT-3') were used to attenuate the 
expression of TWIST1 in OVCA433 cells. Lentiviruses lacking an shRNA 
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sequence (pLKO) as a control, or plasmids containing vimentin hairpins 
(OpenBiosystems; A11 seq:5'-CCGG-GCTAACTACCAAGACACTATT-
CTCGAG-AATAGTGTCTTGGTAGTTAGC-TTTTT-3', B1 seq: 5'-CCGG-
GCAGGATGAGATTCAGAATAT-CTCGAG-ATATTCTGAATCTCATCCTGC-
TTTTT-3', B2 seq: 5'-CCGG-CGCCATCAACACCGAGTTCAA-CTCGAG-
TTGAACTCGGTGTTGATGGCG-TTTTT-3', B3 seq: 5'-CCGG-
GACAGGTTATCAACGAAACTT-CTCGAG-AAGTTTCGTTGATAACCTGTC-
TTTTT-3') were used to attenuate the expression of vimentin in OVCA433 cells. 
Lentiviruses lacking an shRNA sequence (pLKO) as a control, or plasmids 
containing ZEB1 hairpins (Arizona State University; 1 seq: 
CCGGGCAACAATACAAGAGGTTAAACTCGAGTTTAACCTCTTGTATTGTTGC
TTTTT, 2 seq: 
CCGGGCTGCCAATAAGCAAACGATTCTCGAGAATCGTTTGCTTATTGGCAG
CTTTTT, 3 seq: 
CCGGCCTCTCTGAAAGAACACATTACTCGAGTAATGTGTTCTTTCAGAGAGG
TTTTT, 4 seq: 
CCGGGCTGTTGTTCTGCCAACAGTTCTCGAGAACTGTTGGCAGAACAACAG
CTTTTT) were used to attenuate the expression of ZEB1 in OVCA433 cells. 
Lentivirus infected cells were selected in medium containing 1ug/ml puromycin 
(Dulbecco).  
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Quantitative Real Time PCR: 
RNA was isolated from ovarian cancer cells using the Trizol reagent (Invitrogen) 
according to the manufacturers instructions. The RNA was reverse transcribed 
into cDNA using the qScript cDNA Synthesis Kit (Quanta) according to the 
manufacturers instructions. cDNA levels were quantitated by the SYBR green 
method on the T900HT (Life Technologies) in a 384-well format. Triplicate 
samples were quantified along with minus RT and minus template controls. 
Amplification was continued for 40 cycles as follows: 94 °C – 10 s, 55 °C – 15 s, 
65 °C – 30 s. Relative expression was determined by normalizing to the PRLPO 
endogenous control. 
 
Reverse Phase Protein Array: 
A vial of primary ovarian cancer cells from each of the DF lines was thawed and 
plated on 10cm cell culture dishes. After 48 hours, the attached cells were 
trypsinized and split into 3 wells of a 6 well cell culture dish. Cells were allowed to 
re-attach over night to form confluent monolayers. RPPA analysis was performed 
as previously described(64). Briefly, cells were collected by washing with ice-cold 
PBS, scrapping and centrifugation at 900g at 4°C for 10 minutes. Pellets were 
resuspended in RPPA lysis buffer (1% Triton X-100, 50mM HEPES, pH 7.4, 150 
mM NaCl, 1.5mM MgCl2, 1mM EGTA, 100mM NaF, 10mM NaPPi, 10% glycerol, 
1mM Na3VO4, and protease inhibitor (Roche) and incubated on ice with 
occasional shaking for 20 minutes. The lysates were centrifuged at 13,000g, 4°C 
for 10 minutes. Lysed proteins were denatured by adding 1% SDS and boiling for 
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5 minutes. Each sample was diluted in five 2-fold serial dilutions and printed onto 
nitrocellulose-coated glass slides (Grace Biolabs  Bend Oregon) with an 
automated robotic Aushon arrayer (Aushon Biosystems Ballerica MA). Each slide 
was probed with a validated primary and secondary antibody, as described(64); 
151 antibodies were used in total. Signal intensity was measured by scanning the 
slides with ImageQuant (Molecular Dynamics, Sunnyvale, CA) and quantified 
using the MicroVigene automated RPPA module (VigeneTech, Inc., North 
Billerica, MA). Relative protein levels were then determined for each sample. 
Signal intensity data were collected and analyzed using software specifically 
developed for RPPA analyses (http://www.VigeneTech.com).  Log transformed 
intensity data were subjected to Students t-tests in bioConductor R.  Significant 
antibody probes were defined as p<0.05.  Log transformed and centered 
heatmaps were generated using Cluster 3.0 and Java TreeView 1.1.1. 
 
Immunohistochemistry (IHC): 
After institutional review board approval, sections of formalin-fixed, paraffin-
embedded (FFPE) cell blocks (CBs) were obtained from the Cytology Division in 
the Department of Pathology at the Brigham and Women’s Hospital (Boston, MA) 
to evaluate the expression of Vimentin and E-cadherin.  The cell blocks 
corresponded to the ascites from the DF lines utilized in this study. 
Immunohistochemistry was performed using the Envision Plus/Horseradish 
Peroxidase system (Dako, Carpinteria, CA) and a polyclonal/monoclonal 
antibody to Vimentin (Dako, Clone 3B4, 1:400) and E-cadherin (Dako, Clone 
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NCH-38, 1:75) as previously described(37, 60).  In brief, paraffin-embedded 
sections were incubated in hydrogen peroxidase and absolute alcohol for 30 
minutes to block endogenous peroxidase activity. Antigen retrieval was 
performed using pressure cooker pretreatment in a citrate buffer (pH=6.0). 
Tissue sections were subsequently incubated with the primary antibody for 40 
minutes at 25 degrees C. After tris-buffered saline rinses, the tissue was 
incubated using the Envision Plus secondary antibody for 30 minutes, followed 
by diaminobenzidine for 5 minutes. Slides were counterstained with Mayer 
hematoxylin. 
 
Immunofluorescence (IF):  
Cells were fixed with 4% formaldehyde, permeabilized with 0.1% Triton X-100, 
and blocked with blocking buffer (10% BSA and 1% Goat Serum in PBS) for 1 
hour. Cells were then incubated with anti-Pax8 antibody (1:200, Proteintech) for 
1 hour followed by anti- mouse Alexa Fluor 568 secondary antibody (1:300, 
Invitrogen) four 1 hour. Cells were counterstained with DAPI for 15 minutes to 
visualize nuclei. Imaging was performed using a Nikon Ti-E Inverted Motorized 
Widefield Fluorescence Microscope as described above.  
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Chapter 5 
Discussion 
 In this dissertation, I described investigations to elucidate the molecular 
mechanisms governing regulation of mesothelial clearance by ovarian cancer 
spheroids. Crucial to these investigations was the development of an in vitro 
assay that monitors intercalation of pre-clustered ovarian cancer spheroids into 
GFP-expressing mesothelial monolayers, thereby modeling the initial step of 
ovarian cancer metastasis. Time-lapse confocal microscopy revealed that 
ovarian cancer spheroids attach to, intercalate between, and protrude under the 
mesothelial cells in the monolayer, leading to mesothelial cell matrix adhesion 
disassembly and migration away from the invading spheroid. These findings 
represent the first detailed description of the cellular events that occur during 
invasion of mesothelial monolayers by ovarian cancer spheroids. While other 
groups have focused on the molecules that mediate the attachment of ovarian 
cancer spheroids to mesothelial monolayers, we delved deeper to describe the 
mechanisms that regulate invasion of spheroids through the mesothelial 
monolayer to the underlying matrix. We found that !5"1 integrin, myosin IIA and 
talin I are all required for mesothelial clearance. These studies supported the 
hypothesis that actomyosin generated traction force exerted by !5"1 integrin on 
the fibronectin matrix surrounding the mesothelial cells drives this clearance 
event. 
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 To more systematically investigate the mechanisms regulating mesothelial 
clearance, we compared the clearance abilities of a large panel of both primary 
ovarian cancer cell samples and established ovarian cancer cell lines. We found 
that clearance ability was correlated with the expression of epithelial and 
mesenchymal genes and proteins; mesenchymal genes and proteins were 
enriched and epithelial genes and proteins were diminished in clearance-
competent spheroids, while the opposite was observed in clearance-incompetent 
spheroids. Furthermore, we show that there is heterogeneity within the 
populations of tumor cells from individual patient samples; some samples have a 
mixture of both epithelial-like and mesenchymal-like cells and only the 
mesenchymal-like cells clear the mesothelial monolayer. This is the first study to 
correlate mesothelial clearance ability with a transcriptional EMT program in a 
large panel of ovarian cancer cell lines and primary ovarian cancer samples. 
Taken together, these studies provide insights into the mechanisms that may 
drive mesothelial clearance in vivo.  
 
Advantage of Using Primary Cell Samples: 
 For several of our studies, as well as the studies performed by many other 
labs (1-6), established ovarian cancer cell lines were used. Established cell lines 
are convenient to use because they are immortalized, and therefore are able to 
be maintained in cell culture. However, the tumor cells that are able to survive 
and are propagated in culture may represent a small population of cells from the 
original tumor. Furthermore, the cells that do survive may have evolved in culture, 
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so it is unclear to what extent any of the established cell lines reflect the original 
tumor population.  
A second concern about established ovarian cancer cell lines is that many 
of the cell lines we used were derived from multiple different subtypes of ovarian 
cancer (7-11)(Table 5.1). Distinct subtypes of ovarian cancers arise from different 
tissues; for example, serous ovarian cancers are proposed to arise from the 
fallopian tube fimbriae (12, 13), while endometrioid ovarian cancers arise from 
endometrial tissue (14). Differences in the cell-of-origin among the established 
tumor cell lines could mask detection of genes that distinguish clearance-
competent versus clearance-incompetent tumor cells.  
As shown in Table 5.1, the origin of some ovarian cancer cell lines have 
not been documented and interestingly, some established cell lines that have 
long been characterized as ovarian cancer display gene expression programs 
inconsistent with ovarian cancer, suggesting that cultures were mixed or 
mislabeled at some point. For example, the cell line SW626, which is 
characterized as ovarian, is most likely of colonic origin (15). While we didn’t 
detect an enrichment of any tumor sub-type in the clearance-competent or 
incompetent cell lines, the mixed background of the cell lines employed in our 
study was a concern.  
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Cell Line! Clearance-
Competent 
Subtype 
ES-2 Yes Clear cell carcinoma 
CP70 Yes Unknown 
OVCAR3 Yes Serous papillary adenocarcinoma 
OVCA433 Yes Ovarian serous carcinoma 
OV207 Yes Clear cell adenocarcinoma 
A2780 Yes Ovarian adenocarcinoma 
TOV112D Yes Endometrioid adenocarcinoma 
DOV13 Yes Ovarian serous carcinoma 
OVCA432 Yes Ovarian serous carcinoma 
HEYC2 Yes Papillary serous adenocarcinoma 
OV2008 Yes Poorly differentiated endometrioid adenocarcinoma  
OVSAHO No Serous papillary adenocarcinoma 
C13 No Endometrioid carcinoma  
OAW28 No Unknown 
PEO6 No Well differentiated adenocarcinoma 
CAOV3 No Ovarian adenocarcinoma 
OVCA429 No Clear cell adenocarcinoma 
EFO21 No Ovarian serous cystadenocarcinoma 
MCAS No Mucinous cystadenocarcinoma, papillary adenocarcinoma 
RMG1 No Ovarian clear cell 
Table 5.1: Subtypes of Ovarian Cancer Cell Lines.  
 
 To circumvent these issues and more directly assess the relevance of our 
findings to human ovarian cancer, we chose to examine primary ovarian cancer 
cell samples that were all derived from patients with serous ovarian carcinoma. In 
agreement with the data from the established cell lines, we observed a wide 
range of clearance activity in the primary ovarian cancer cell samples, suggesting 
that differences in clearance ability was not due to the different origins of the 
established cell lines. We did not carry out genome-wide microarrays on the 
primary ovarian cancer tumor samples; however, in the future, it would be useful 
to perform RNA sequencing on these samples to further define the gene 
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programs that distinguish clearance-competent from clearance-incompetent 
tumor cells.  
 
Unanswered Questions/ Future Studies: 
Role of Force In Mesothelial Clearance:  
In Chapter 3, we showed that actomyosin generated contractile force is 
required for mesothelial clearance. This finding raised several unanswered 
questions: Is the mechanical force exerted by ovarian cancer spheroids on the 
fibronectin surrounding the mesothelial cells sufficient to cause mesothelial 
clearance? Is force exerted by !5"1 integrin the only mechanical stimulation 
involved in clearance of the mesothelial monolayer or does, for example, 
protrusive force generated by actin polymerization play a role? Finally, is 
mechanical force the only mechanism acting on the mesothelial cells to promote 
mesothelial clearance, or are there other molecules on the ovarian cancer cells 
that induce the retraction of the mesothelial monolayer?  
 To test the mechanical force hypothesis directly, magnetic tweezers, 
similar to the apparatus described in Kollmannsberger and Fabry(16), could be 
used to apply linear, nanonewton-scale forces to the mesothelial monolayers. 
Two types of force can be exerted on the mesothelial monolayer by the 
spreading ovarian cancer spheroids: [A] actomyosin contractility exerts force on 
integrin-based focal adhesions, which in turn exerts a pulling force on the ECM 
molecules surrounding the mesothelial cells or [B] ovarian cancer spheroid 
protrusion exerts a pushing force on the surrounding mesothelial cells via actin 
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polymerization against the ovarian cancer cell membrane(17-19). A pulling force 
can be applied to the ECM surrounding the mesothelial cells by using a magnetic 
bead coated with !1-integrin, to determine if pulling on the fibronectin 
surrounding mesothelial cells is sufficient to induce mesothelial clearance. On the 
other hand, an uncoated magnetic bead can be used to apply a pushing force, 
similar in magnitude to protrusive force, to the mesothelial cells to determine if a 
pushing force directly on the mesothelial cells is sufficient to induce mesothelial 
clearance.  
  Independently of whether or not mechanical force is sufficient to induce 
mesothelial clearance, it is possible that signaling molecules present on the 
ovarian cancer spheroids induce the mesothelial cells to retract away from the 
invading spheroid. It is unlikely that this is a soluble factor, since either incubating 
mesothelial monolayers with ovarian cancer spheroid conditioned media (data 
not shown) or with spheroids that are intact but unable to spread (due to "5!1 
integrin, talin I or myosin II inhibition, Chapter 3) does not induce retraction of the 
mesothelial cells. Many cell membrane proteins have been implicated in cell-cell 
repulsion, including members of the ephrin and semaphorin families (20, 21). 
Interestingly, ephrins and semaphorins are up-regulated in some metastatic 
tumors (21, 22). These ligands and their receptors can be inhibited in the 
spheroids and mesothelial cells to determine if repulsion plays a role in 
mesothelial clearance.  
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Effect of Force on Ovarian Cancer Spheroid Behavior: 
 Thus far, our experiments have focused on the mechanisms by which 
invading ovarian cancer spheroids affect the behavior of the mesothelial 
monolayer. We have not, however, determined how the migratory properties of 
the mesothelial cells affect the behavior of the ovarian cancer spheroids. There is 
experimental evidence that force can promote the invasive behavior of cancer 
cells (23). Menon et al. applied a mechanical stimulus to the fibronectin 
surrounding cancer cells on a collagen I bed, by pulling on magnetic beads 
embedded in the collagen matrix. The authors found that human fibrosarcoma 
cells became more invasive when the force was applied, and fibronectin was 
required for this increased invasive capacity, suggesting that the cancers cells 
sensed and responded to the force exerted on the fibronectin in the collagen gel 
(23). The mesothelial cells in our clearance assay are not static; they are 
constantly moving within the monolayer (Chapter 3). It is likely that the 
mesothelial cells exert force on the stromal fibronectin, which is sensed by the 
invading ovarian cancer spheroids. It would be interesting to determine if the 
force exerted by the mesothelial cells promotes ovarian cancer spheroid invasion.    
 
Epithelial and Mesenchymal Cell States in Ovarian Cancer: 
In chapter 4, we found that some ovarian cancer cell lines express a 
mesenchymal-like gene signature while other ovarian cancer cell lines express 
an epithelial-like gene signature. Similarly, in primary ovarian cancer cell samples 
derived from patients with high-grade serous ovarian cancer, some samples 
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express vimentin, while others express E-cadherin. In addition, some tumors 
contained cells that express both markers, either in the same cells or in two 
adjacent populations. This degree of heterogeneity raises questions about the 
mechanisms responsible for the distinct differences in epithelial and 
mesenchymal markers in different patient tumors.  Interestingly, the proposed 
‘cells of origin’ of high-grade serous ovarian cancer are mesoepithelial cells that 
express both E-cadherin and vimentin [Figure 5.1, images adapted from images 
obtained from the Human Protein Atlas (www.proteinatlas.org) (24)]. This is in 
contrast to luminal epithelial cells of the breast and their progenitors that do not 
express vimentin [Figure 5.1, images adapted from images obtained from the 
Human Protein Atlas (www.proteinatlas.org) (24)]. Given the proposed 
mesoepithelial origin of high-grade serous ovarian cancer cells, these cells may 
be more plastic in shifting between predominantly epithelial or mesenchymal 
programs when adapting to different microenvironmental conditions. In contrast, 
since the cell-of-origin of most breast tumors are purely epithelial, conversion to a 
mesenchymal phenotype may involve distinct mechanisms relative to ovarian 
tumors.    
Investigations from one laboratory provided evidence that ovarian cancer 
cells display more epithelial-like features in the ascites of ovarian cancer patients, 
and display more mesenchymal-like features in metastases. Elloul et al. 
measured the mRNA and protein expression of E-cadherin and SNAI1 in 
different stages of ovarian cancer progression. They found that E-cadherin 
expression was higher in tumor cells within ascites fluid compared to the primary 
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tumor and metastases. They also found that SNAI1 expression was lower in the 
ascites samples compared to the primary tumor and metastases (25). In a 
separate study, Elloul et al. found that TWIST1 and ZEB1 mRNA expression was 
higher in the metastases, compared to the primary tumor and ascites samples 
(26). It is difficult to draw conclusions about the processes responsible for 
mesenchymal and epithelial cell states in the primary, ascites and metastatic 
samples, however, because we cannot follow the fate of individual cells. The 
different microenvironments in the primary tumor, ascites, and metastatic site 
may select for cells that are either more mesenchymal or more epithelial, or 
EMT/MET switches may occur between the primary tumor, ascites, and 
metastatic sites.  
To address this question, a transgenic mouse model can be developed 
that tags fallopian tube cells and follows their neoplastic progression. An rtTA-
Pax8 mouse, tet-On-Cre mouse is commercially available (27) that can be used 
to express genes of interest, selectively, in the secretory cells of the fallopian 
tube, the cells of origin of serous ovarian cancer. These mice can be crossed 
with mice harboring constructs containing Lox-Stop-Lox plus genes that are 
commonly mutated in ovarian cancer and a fluorescent marker such as a GFP 
gene. A similar system has been used for stem cell lineage tracing (28). The 
correct combination of mutations expressed in the fallopian tube cells should 
create fallopian tube tumors that mimic ovarian cancer progression. Kim and 
colleagues created a mouse model of serous ovarian cancer by knocking out 
Pten and Dicer in fallopian tube cells (29). A fluorescent marker, such as GFP, 
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could be added where Pten or Dicer was knocked out to trace the lineage of 
carcinomas developed in these mice. The epithelial and mesenchymal states of 
the fluorescent cells can then be followed over time, to determine if there is a 
progressive switch between epithelial and mesenchymal cell states at different 
stages of ovarian cancer progression.   
 
In vivo Relevance: 
Is mesothelial clearance by mesenchymal-like ovarian cancer cells required for 
ovarian cancer metastasis in vivo? 
 We have shown that the expression of mesenchymal markers and the 
repression of epithelial markers are correlated with the mesothelial clearance 
ability of ovarian cancer spheroids in vitro. Furthermore, overexpression of EMT-
inducing transcription factors promotes mesothelial clearance ability in ovarian 
cancer spheroids that were unable to clear a mesothelial monolayer. We did not, 
however, investigate the ability of EMT to regulate mesothelial clearance in vivo.  
 Shao and colleagues used a mouse xenograft model to investigate the 
role of EMT in ovarian cancer metastasis (30). They found that TG2 
overexpression promotes EMT in OV90 ovarian cancer cells, while TG2 
knockdown represses EMT in SKOV3 ovarian cancer cells. When control or 
TG2-knockdown SKOV3 cells were injected orthotopically under the ovarian 
bursa of nu/nu BALB/c nude mice, TG2 knockdown suppressed the formation of 
metastatic implants on the omentum, mesentery, and peritoneal surface of the 
abdominal cavity. (It is of note that the SKOV3 cells were serially passaged 
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through the mouse one time before they were able to produce metastasis from 
the ovarian bursa xenografts.) This data suggests EMT repression blocks ovarian 
metastasis formation in a mouse xenografts model.  
 An ovarian xenograft model such as the one described above could be 
used to address many questions regarding the relevance of EMT in ovarian 
cancer progression. First, mesothelial clearance-incompetent ovarian cancer 
cells could be injected into the ovarian bursa or within the peritoneal cavity fluid 
to determine if those cells produce peritoneal metastases. Furthermore, the 
ability of the ovarian cancer cells to clear the mesothelial layer in vivo could be 
monitored by excising the nodules attached to the peritoneal cavity organs (if 
any) and looking for the presence or absence of mesothelial cells under the 
attached nodules by IHC. In addition, the effect of EMT on mesothelial clearance 
in vivo can be tested by injecting clearance-incompetent cell lines that over-
express an EMT-inducing transcription factor into mice. The ability to form 
metastasis and the presence or absence of mesothelial cells under metastatic 
nodules can then be compared between control and EMT transcription factor-
overexpressing ovarian cancer cells to determine if EMT promotes metastasis 
and/ or mesothelial clearance in vivo.  
 This model system could also be used to determine if EMT/MET 
interconversion occurs during metastatic progression. The ovarian cancer cell 
line MCAS is epithelial-like and clearance-incompetent in our mesothelial 
clearance assay, yet it is able to form tumors after intraperitoneal injection in 
nude mice. It would be interesting to determine, first, if these cells are able to 
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clear the peritoneal mesothelial cells in vivo, and then, if an EMT event is 
required in order for mesothelial clearance/ and or seeding of metastatic nodules 
to occur. The expression of epithelial and mesenchymal markers can be 
compared between the MCAS cells in suspension in the peritoneal cavity and the 
MCAS cells that have attached to the peritoneal cavity organs at various time 
points after metastasis. 
  
Do First-line Treatments Promote Metastasis? 
 Two interesting observations suggest that treatments that are used as a 
first-line defense against ovarian cancer may be detrimental to the patient by 
promoting ovarian cancer metastasis: Latifi et al. found that clinical samples, as 
well as the OVCA433 ovarian cancer cell line, upregulated mesenchymal 
markers such as Snail, Slug, Twist and vimentin and downregulated E-cadherin, 
when treated with the chemotherapeutic drug, cisplatin (31). Similarly, Slug was 
upregulated in mouse ovarian carcinoma xenografts treated with the 
chemotherapeutic drug, Paclitaxel (32). These data indicate that 
chemotherapeutic drugs either promote EMT in ovarian cancer cells, or kill only 
the epithelial-like ovarian cancer cells while allowing resistant mesenchymal-like 
cells to take over the population. This would complicate the analysis, described 
above, to determine when EMT and MET occur during ovarian cancer 
progression, since most ovarian cancer patients are treated with 
chemotherapeutics. A larger concern is that the therapeutics that are supposed 
to treat ovarian cancer may promote ovarian cancer metastasis. It is, therefore, 
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very important to perform an in vivo analysis where samples are collected from 
ovarian cancer patients before and after treatment with chemotherapeutic drugs 
when metastases recur. Mesenchymal and epithelial markers should be 
measured by IHC in those samples to determine if chemotherapeutic agents are 
promoting EMT in ovarian cancer cells. 
 
EMT status and ability to debulk tumors in vivo:  
 Currently, the only treatment options for ovarian cancer are cytoreductive 
surgery followed by platinum/taxane-based chemotherapy (33-35). Improved 
survival directly correlates with the amount of tumor bulk that can be resected (36, 
37). It would be interesting to determine if the extent of debulking correlates with 
the expression of epithelial or mesenchymal markers. To perform this analysis, 
the expression of epithelial and mesenchymal markers should be measured in 
samples that were collected during debulking under conditions where the 
surgeon measures the percentage of residual tumor after surgery. Our data 
suggests that mesenchymal-like cells are able to clear a mesothelial monolayer 
better than epithelial-like cells. This could indicate that mesenchymal-like cells 
are able to intercalate into peritoneal cavity organs better than epithelial-like cells, 
but it will have to be tested in mouse models (as described above) and by 
collecting ovarian cancer patient data. 
 Finally, since we have shown that mesenchymal-like cells more efficiently 
clear mesothelial monolayers, this raises the question of whether blocking the 
mesenchymal program in ovarian cancer cells within the ascites could prevent 
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re-seeding of tumors after debulking and chemotherapy? Several drugs, 
including metformin, TGF-! inhibitors, and other small molecules inhibitors have 
been show to reverse EMT in various contexts (38-40). Inhibitors such as these 
should be tested to evaluate their ability to reverse EMT in ovarian cancer cells. 
A drug, or combination of drugs, that can reverse EMT can then be tested in 
combination with current treatment methods to determine if tumor re-seeding can 
be reduced.  
 
Assay Limitations: 
The mesothelial clearance assay described in this dissertation uses a 
minimal number of components to model the interaction between two cell types, 
ovarian cancer spheroids and a mesothelial monolayer. But there are other 
components of the peritoneal organs that may play a role in metastasis. Below 
the mesothelial monolayer there is a basement membrane composed of ECM 
molecules including collagen types I and IV, laminin and fibronectin, and 
dispersed within the ECM are fibroblasts and macrophages. Our in vitro assay 
seeds the mesothelial cells directly on a glass-bottom cell culture plate coated 
with a thin layer of fibronectin. The stiffness of a glass substrate is much stiffer 
than the basement membrane underlying the mesothelial monolayers in vivo (41), 
so it is possible that the ovarian cancer spheroids would behave differently on a 
more physiologically relevant substrate. To address this issue, we plated 
mesothelial monolayers on fibronectin-coated polyacrylamide gels with elastic 
moduli of 0.3 kPa or 10 kPa, similar substrate stiffness to connective tissue 
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(Chapter 3). OVCA433 spheroids were able to clear the mesothelial monolayers 
seeded on these physiologically relevant substrates, suggesting that mesothelial 
clearance is not an artifact of an artificially stiff substrate.  
 Kenny et al. developed a 3D in vitro model system (42, 43) that included 
more of the components of the peritoneal tissue than were included in our 
system. A bed of collagen I was deposited between the culture dish and the 
mesothelial monolayer, and fibroblasts were suspended within the collagen bed. 
A single cell suspension of ovarian cancer cells were added on top of the 
monolayers and allowed to invade. The authors found that the mesothelial 
monolayer dampened ovarian cancer cell invasion into the collagen bed 
compared to invasion into collagen that was not covered with a mesothelial 
monolayer. Interestingly, fibroblasts suspended in the collagen bed promoted 
adhesion and invasion compared to adhesion and invasion in wells where 
fibroblasts were left out of the collagen mix (43). However, the authors only 
monitored the invasion of single ovarian cancer cells in this model. It would be 
interesting to monitor the behavior of ovarian cancer multicellular spheroids in 
this model system to determine how the ovarian cancer spheroids behave in a 
more physiologically relevant context. Furthermore, it would be interesting to 
determine if the cutoff between the established and primary ovarian cancer 
spheroids that were clearance-competent versus clearance-incompetent would 
shift on the more compliant surface. It is possible that the cell lines that are able 
to clear, but are close to the cutoff (ex. HeyC2, OVCA432), would be unable to 
clear on the more compliant surface.  
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 The model described by Kenny et al. does not include all of the 
components present in the peritoneal tissue. Below the mesothelial monolayer 
there is a dense layer of basement membrane that includes not only collagen 
and fibroblasts, but fibronectin, laminin and macrophages, as well (44, 45). A 
model system that incorporates all of these cell types would be more 
physiologically relevant than the ones described above.   
 Interestingly, in vivo, ovarian cancer spheroids preferentially home to the 
omentum, a soft pad of tissue in the peritoneum that has a thick layer of 
adipocytes directly under the mesothelial monolayer and basement membrane 
(46). Nieman and colleagues showed that Il-6 and Il-8, two cytokines that are 
secreted by the adipocytes, promote ovarian cancer cell homing to the omentum 
(46). It would be interesting to add a layer of adipocytes to the in vitro model to 
determine the effect of adipocytes homing and cytokine release on mesothelial 
clearance. It is possible that cell lines with different genetic backgrounds would 
respond differently to the addition of adipocytes.   
 
Future Applications of Mesothelial Clearance Assay: 
 The mesothelial clearance assay can be easily adapted for drug screening 
by converting it to an automated, high-throughput assay. Robots can be used to 
automatically plate ovarian cancer cells in large quantities of 384-well low-
adhesion culture plates to form spheroids and to coat 384-well plates with 
fibronectin and plate mesothelial cells in those wells. Robots can also be used to 
transfer the spheroids from the low adhesion culture plates to the monolayer 
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containing plates. The addition of different drugs or small molecules to each well 
of the 384 well assay plates can be similarly automated. Different libraries of 
drugs and small molecules can then be tested to determine their effects on 
mesothelial clearance. If certain drugs or small molecules can inhibit mesothelial 
clearance, they may be good candidates for new ovarian cancer metastasis 
treatments.  
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Appendix 
Supplementary Materials 
 
Supplementary Materials for Chapter 2 
SUPPLEMENTARY MOVIE 2.1: Video prepared for peer reviewed, PubMed-
indexed video journal, JoVE. 
 
Supplementary Materials for Chapter 3 
SUPPLEMENTARY MOVIE 3.1: OVCA433 cancer spheroids clear the 
mesothelium. Cancer spheroids (red) were allowed to adhere to mesothelial 
monolayer. The interaction between the two cell populations was recorded over a 
10 hour period. Movie shows a montage of phase image (top), red-labeled 
spheroid image, GFP-labeled mesothelium image and pseudo-colored overlay of 
spheroid and mesothelium image.  
 
SUPPLEMENTARY MOVIE 3.2: Freshly isolated spheroids from peritoneal 
effusion of ovarian cancer patient were labeled (as described in methods) and 
allowed to interact with the mesothelial monolayer for a period longer than 10 
hours. Movie shows montage of phase image (top), cancer spheroid (middle) and 
mesothelium (bottom).  
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SUPPLEMENTARY MOVIE 3.3: Side view reconstruction of mesothelial 
clearance by OVCA433 spheroids. 30 focal planes were reconstructed on x-z 
plane to observe cell interactions at the ventral and dorsal cell surfaces of 
mesothelial monolayer. Each plane is 1 um apart. Bar =100 µm.  
 
SUPPLEMENTARY MOVIE 3.4: TIRFM of mesothelial cell (LP9) focal adhesions 
(green as labeled by GFP-Paxillin) in the presence of OVCA433 cancer spheroid 
membrane protrusions (red).  
 
 
SUPPLEMENTARY MOVIE 3.5: TIRFM of mesothelial cell focal adhesions 
(labeled by GFP-Paxillin) in the absence of OVCA433 cancer spheroid.  
 
SUPPLEMENTARY MOVIE 3.6: OVCA433 spheroids provoke migration of 
mesothelial cells away from spheroid attachment sites. Time lapse recording of 
GFP-Labeled mesothelial cells in the absence and presence of intercalating 
OVCA433 spheroid (red). Bar = 100 µm.  
 
SUPPLEMENTARY MOVIE 3.7: Myosin II is required for cancer spheroid to 
induce mesothelial clearance. Time lapse recording of control RNAi and NMIIA/B 
RNAi treated OVCA433 (red) spheroids intercalating into mesothelial monolayer 
(green).  Top recording represents DIC image. Bar = 100µm.  
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SUPPLEMENTARY MOVIE 3.8:  Talin I is required for cancer spheroids to 
induce mesothelial clearance. Time-lapse recording of control RNAi and Talin I 
RNAi treated OVCA433 (red) spheroids intercalating into mesothelial monolayer 
(green). Top recording represent DIC image. Bar=100µm.  
 
SUPPLEMENTARY MOVIE 3.9: Blocking !5"1 integrin in OVCA433 spheroids 
attenuates mesothelial clearance. OVCA433 spheroids were pretreated with IgG 
and ITGA5 function blocking antibody. Top recording shows DIC image and 
bottom recording shows clearance of mesothelial cells (green). Bar=100µm.  
 
SUPPLEMENTARY MOVIE 3.10:  Ectopic expression of ITGA5 in OVCAR5 
spheroids is sufficient to promote mesothelial clearance. Top recordings 
represents DIC image series of OVCAR5 cells expressing either empty plasmid 
or plasmid encoding ITGA5. Bottom recordings represent florescent image series 
of GFP – labeled mesothelial cells. Bar = 100µm.  
 
SUPPLEMENTARY MOVIE 3.11: Laser Scanning Confocal microscopy of 
intercalated OVCA433 spheroid (blue) into mesothelial monolayer (green) and 
fibronectin (red). There were 30 z planes acquired. Each plane was 1µm apart. 
Bar = 10µm.  
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SUPPLEMENTARY MOVIE 3.12: Spinning Disc Confocal Microscopy of 
intercalating OVCA433 spheroid (blue) into rhodamine-labeled fibronectin (red) 
covered mesothelium (green). 
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Supplementary Materials for Chapter 4 
SUPPLEMENTARY MOVIE 4.1: Composite of representative movies of 
mesothelial clearance by ovarian cancer cell lines in order of clearance ability 
from left to right, top to bottom: ES2, CP70, OVCAR3, OVCA433, OV207, A2780, 
TOV112D, DOV13, OVCA432, HEYC2, OV2008, OVSAHO, C13, OAW28, 
PE06, CAOV3, OVCA429, EFO21, MCAS, RMG1.  
 
SUPPLEMENTARY MOVIE 4.2: Composite of representative movies of 
mesothelial clearance by primary ovarian cancer cell samples in order of 
clearance ability from left to right, top to bottom: DF168, DF106, DF164, DF29, 
DF163, DF24, DF43, DF173, DF143, DF155, DF166, DF118, DF59, DF141, 
DF68, DF160, DF176, DF9, DF172, DF147, DF14.  
 
SUPPLEMENTARY TABLE 4.1: Genes identified that distinguish the clearance-
competent cell lines from the clearance-incompetent cell lines.  
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